

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 471/08, 471/20, A61K 31/435		A1	(11) International Publication Number: WO 99/31100 (43) International Publication Date: 24 June 1999 (24.06.99)
(21) International Application Number: PCT/SE98/02276		(74) Agent: ASTRA AKTIEBOLAG; Patent Dept., S-151 85 Södertälje (SE).	
(22) International Filing Date: 10 December 1998 (10.12.98)		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(30) Priority Data: 9704709-6 17 December 1997 (17.12.97) SE		(71) Applicant (<i>for all designated States except US</i>): ASTRA AKTIEBOLAG [SE/SE]; S-151 85 Södertälje (SE). (72) Inventors; and (75) Inventors/Applicants (<i>for US only</i>): STRANDLUND, Gert [SE/SE]; Astra Hässle AB, S-431 83 Mölndal (SE). AL-STERMARK, Christer [SE/SE]; Astra Hässle AB, S-431 83 Mölndal (SE). BJÖRE, Annika [SE/SE]; Astra Hässle AB, S-431 83 Mölndal (SE). BJÖRSNE, Magnus [SE/SE]; Astra Hässle AB, S-431 83 Mölndal (SE). FRANTSJ, Marianne [SE/SE]; Astra Hässle AB, S-431 83 Mölndal (SE). HAL-VARSSON, Torbjörn [SE/SE]; Astra Hässle AB, S-431 83 Mölndal (SE). HOFFMANN, Kurt-Jürgen [DE/SE]; Astra Hässle AB, S-431 83 Mölndal (SE). LINDSTEDT, Eva-Lotte [SE/SE]; Astra Hässle AB, S-431 83 Mölndal (SE). POLLA, Magnus [SE/SE]; Astra Hässle AB, S-431 83 Mölndal (SE).	

(54) Title: NOVEL BISPIDINE ANTIARRHYTHMIC COMPOUNDS



(57) Abstract

There is provided a compound of formula (I), wherein R¹, R², R⁹, R¹⁰, R¹¹, R¹², X, A and B have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

NOVEL BISPIDINE ANTIARRHYTHMIC COMPOUNDS

Field of the Invention

5

This invention relates to novel pharmaceutically useful compounds, in particular compounds which are useful in the treatment of cardiac arrhythmias.

10 Background and Prior Art

Cardiac arrhythmias may be defined as abnormalities in the rate, regularity, or site of origin of the cardiac impulse or as disturbances in conduction which causes an abnormal sequence of activation. Arrhythmias may be 15 classified clinically by means of the presumed site of origin (i.e. as supraventricular, including atrial and atrioventricular, arrhythmias and ventricular arrhythmias) and/or by means of rate (i.e. bradyarrhythmias (slow) and tachyarrhythmias (fast)).

20 In the treatment of cardiac arrhythmias, the negative outcome in clinical trials (see, for example, the outcome of the Cardiac Arrhythmia Suppression Trial (CAST) reported in New England Journal of Medicine, 321, 406 (1989)) with "traditional" antiarrhythmic drugs, which act primarily by slowing the conduction velocity (class I antiarrhythmic drugs), has prompted 25 drug development towards compounds which selectively delay cardiac repolarization, thus prolonging the QT interval. Class III antiarrhythmic drugs may be defined as drugs which prolong the trans-membrane action potential duration (which can be caused by a block of outward K⁺ currents

2

or from an increase of inward ion currents) and refractoriness, without affecting cardiac conduction.

One of the key disadvantages of hitherto known drugs which act by delaying s repolarization (class III or otherwise) is that they all are known to exhibit a unique form of proarrhythmia known as *torsades de pointes* (turning of points), which may, on occasion be fatal. From the point of view of safety, the minimisation of this phenomenon (which has also been shown to be exhibited as a result of administration of non-cardiac drugs such as 10 phenothiazines, tricyclic antidepressants, antihistamines and antibiotics) is a key problem to be solved in the provision of effective antiarrhythmic drugs.

Most antiarrhythmic drugs (including class III antiarrhythmic drugs) have a duration of action of between 3 and 12 hours. For example, the recently 15 registered (approved, as of December 1997, in the US, Sweden, the UK, Denmark, Belgium, Netherlands, Finland, Italy and Austria) selective class III antiarrhythmic drug ibutilide (Pharmacia Upjohn) has a half-life of elimination which averages at around 6 hours when the drug is administered intravenously to a human patient.

20

In the minimisation of the side effects (including *torsades de pointes*) associated with antiarrhythmic drugs, compounds which are effective, yet short acting, when administered intravenously, are expected to be of benefit. Accordingly, compounds which have a duration of action which is 25 relatively short (hereinafter referred to as "short acting compounds") may be expected to have clinical advantages when used in the acute conversion of arrhythmias, including reduced monitoring and hospitalisation time. By "short acting" in this context, we mean a half life ($t_{1/2}$), as measured in the test described below, of between 1 and 120 minutes, preferably between 1

3

and 60 minutes, more preferably between 1 and 30 minutes and especially between 1 and 15 minutes.


Antiarrhythmic drugs based on bispidines (3,7-diazabicyclo[3.3.1]nonanes),
5 are known from *inter alia* international patent application WO 91/07405,
European patent applications 306 871, 308 843 and 655 228 and US patents
3,962,449, 4,556,662, 4,550,112, 4,459,301 and 5,468,858, as well as
journal articles including *inter alia* J. Med. Chem. 39, 2559, (1996),
Pharmacol. Res., 24, 149 (1991), Circulation, 90, 2032 (1994) and Anal.
10 Sci. 9, 429, (1993). Known bispidine-based antiarrhythmic compounds
include bisaramil (3-methyl-7-ethyl-9 α ,4'-(Cl -benzoyloxy)-3,7-
diazabicyclo[3.3.1]nonane), tedisamil (3',7'-bis(cyclopropylmethyl)spiro-
(cyclopentane-1,9'-3,7)diazabicyclo-[3.3.1]nonane), SAZ-VII-22 (3-(4-
chlorobenzoyl)-7-isopropyl-3,7-diazabicyclo[3.3.1]nonane), SAZ-VII-23 (3-
15 benzoyl-7-isopropyl-3,7-diazabicyclo[3.3.1]nonane), GLG-V-13 (3-[4-(1H-
imidazol-1-yl)benzoyl]-7-isopropyl-3,7-diazabicyclo[3.3.1]nonane), KMC-
IV-84 (7-[4'-(1H-imidazolo-1-yl)benzenesulphonyl]-3-isopropyl-3,7-diaza-
bicyclo[3.3.1]nonane dihydro-perchlorate and ambasilide (3-(4-
aminobenzoyl)-7-benzyl-3,7-diazabicyclo[3.3.1]nonane).

20

We have surprisingly found that a novel group of bispidine-based
compounds exhibit electrophysiological activity, preferably class III
electrophysiological activity, and in particular short-acting class III
electrophysiological activity, and are therefore expected to be useful in the
25 treatment of cardiac arrhythmias.

Disclosure of the Invention

According to the invention there is provided a compound of formula I,



wherein

- R¹ and R² independently represent H, C₁₋₄ alkyl or together form -O-(CH₂)₂-O-, -(CH₂)₄- or -(CH₂)₅-;
- 10 R⁹ represents C₁₋₁₂ alkyl, phenyl, naphthyl, C₁₋₃ alkylphenyl (which four groups are all optionally substituted or terminated by one or more substituents selected from -OH, halo, cyano, nitro, C₁₋₄ alkyl or C₁₋₄ alkoxy) or -(CH₂)_qCy¹;
- R¹⁰ represents H or -OH;
- 15 R¹¹ represents H or C₁₋₄ alkyl;
- R¹² represents one or more optional substituents selected from OH, cyano, halo, amino, nitro, C₁₋₆ alkyl, C₁₋₆ alkoxy, -N(H)S(O)₂R¹⁶, -OS(O)₂R^{16a}, -N(H)C(O)N(H)R¹⁷ or -C(O)N(H)R¹⁸;
- A represents a single bond, C₁₋₄ alkylene, -(CH₂)_nN(R²⁰)-, -(CH₂)_nS(O)_p-,
- 20 -(CH₂)_nO- (in which three latter groups, the -(CH₂)_n- group is attached to the carbon atom bearing R¹⁰ and R¹¹), -C(O)N(R²⁰)- (in which latter group, the -C(O)- group is attached to the carbon atom bearing R¹⁰ and R¹¹),

5

-N(R²⁰)C(O)O(CH₂)_n- , -N(R²⁰)(CH₂)_n- (in which two latter groups, the N(R²⁰) group is attached to the carbon atom bearing R¹⁰ and R¹¹) or -(CH₂)_mC(H)(OH)(CH₂)_n- (in which latter group, the -(CH₂)_m- group is attached to the carbon atom bearing R¹⁰ and R¹¹);

5 B represents a single bond, C₁₋₆ alkylene, -N(R²³)(CH₂)_r- or -O(CH₂)_r- (in which two latter groups, the -(CH₂)_r- group is attached to the bispidine nitrogen atom);

m represents 1, 2 or 3;

n and r independently represent 0, 1, 2, 3 or 4;

10 p represents 0, 1 or 2;

q represents 0, 1, 2 or 3;

X represents O or S;

Cy¹ represents a five to seven-membered heterocyclic ring containing one or more heteroatom selected from O, N or S, which ring is optionally substituted by one or more substituent selected from C(O)R²¹ or C(O)OR²²;

15 R¹⁶, R^{16a}, R²⁰ and R²³ independently represent H or C₁₋₄ alkyl; and R¹⁷, R¹⁸, R²¹ and R²² independently represent H or C₁₋₆ alkyl; or a pharmaceutically acceptable derivative thereof.

20

Pharmaceutically acceptable derivatives include salts and solvates. Salts which may be mentioned include acid addition salts. Pharmaceutically acceptable derivatives also include, at the bispidine nitrogens, C₁₋₄ alkyl quaternary ammonium salts and N-oxides, provided that, when a N-oxide is present at a bispidine nitrogen, X does not represent S and/or p does not represent 0 when A represents -(CH₂)_nS(O)_p-.

The compounds of the invention may exhibit tautomerism. All tautomeric forms and mixtures thereof are included within the scope of the invention.

The compounds of the invention may also contain one or more asymmetric carbon atoms and may therefore exhibit optical and/or diastereoisomerism.

Diastereoisomers may be separated using conventional techniques, e.g.

5 chromatography or fractional crystallisation. The various stereoisomers may be isolated by separation of a racemic or other mixture of the compounds using conventional, e.g. fractional crystallisation or HPLC, techniques.

Alternatively the desired optical isomers may be made by reaction of the appropriate optically active starting materials under conditions which will

10 not cause racemisation or epimerisation, or by derivatisation, for example with a homochiral acid followed by separation of the diastereomeric esters by conventional means (e.g. HPLC, chromatography over silica). All stereoisomers are included within the scope of the invention.

15 Alkyl groups which R¹, R², R⁹, R¹¹, R¹², R¹⁶, R^{16a}, R¹⁷, R¹⁸, R²⁰, R²¹, R²² and R²³ may represent, and with which R⁹ may be substituted, may be linear or branched, may be saturated or unsaturated, may be cyclic, acyclic or part cyclic/acyclic, and may be interrupted by oxygen and/or substituted by one or more fluoro or hydroxy group. Alkylene groups

20 which A and B may represent, and -(CH₂)_m- , -(CH₂)_n- , -(CH₂)_q- and -(CH₂)_r- chains which A, B and R⁹ (as appropriate) may include, may be linear or branched, may be saturated or unsaturated, may be cyclic or acyclic and may be interrupted by oxygen. Alkoxy groups which R¹² may represent, and with which R⁹ may be substituted, may be linear or

25 branched, may be saturated or unsaturated and may be cyclic or acyclic. Alkylphenyl groups which R⁹ may represent may be linear or branched and may be saturated or unsaturated.

Heterocyclic groups which Cy¹ may represent may be aromatic or non-aromatic in character.

Halo groups which R¹² may represent, and with which R⁹ may be
5 substituted, include fluoro, chloro, bromo and iodo.

Abbreviations are listed at the end of this specification.

Preferred compounds of the invention include those in which:

10 R¹ represents H, C₁₋₄ alkyl or, together with R², represents -O(CH₂)₂O- or -(CH₂)₄-;

R² represents H or together with R¹ represents -O(CH₂)₂O- or -(CH₂)₄-;

15 R⁹ represents optionally substituted phenyl, optionally substituted C₁₋₃ alkylphenyl, optionally substituted, optionally unsaturated, linear, branched or cyclic, C₁₋₁₂ alkyl (which latter group may also be interrupted by an O atom), or -(CH₂)_qCy¹;

R¹¹ represents H, CH₃ or CH₂OH;

R¹² is absent or represents one or more substituents selected from cyano, OH, nitro, N(H)S(O)₂R¹⁶, N(H)C(O)N(H)R¹⁷, C(O)N(H)R¹⁸, OS(O)₂R^{16a}, 20 amino and C₁₋₆ alkyl;

X represents O;

A represents a single bond, O, -CH₂-, -(CH₂)₂-, -CH₂O-, -(CH₂)₂O-, -CH₂S-, -CH₂N(R²⁰)-, -C(O)N(R²⁰)-, -N(R²⁰)C(O)O(CH₂)_n-, -CH₂CH(OH)- or N(R²⁰)(CH₂)_n-;

25 B represents optionally unsaturated, linear or branched, C₁₋₄ alkylene (which group is also optionally interrupted by O);

when the bispidine nitrogen bearing B optionally bears a C₁₋₄ alkyl group, thus forming a quaternary ammonium salt, the alkyl group is a methyl group.

When R¹² represents a substituent in the *para* position (e.g. when a single substituent is present in this position), preferred substituents include cyano, nitro and N(H)S(O)₂R¹⁶ (in which latter group R¹⁶ represents C₁₋₃ alkyl, especially methyl, ethyl or *n*-propyl).

When R⁹ represents -(CH₂)_qCy¹, preferred compounds of the invention include those in which q is 0, 1 or 2 and Cy¹ contains at least one nitrogen atom (e.g. Cy¹ represents a six-membered ring containing one or two nitrogen atoms). Preferred ring systems that may be represented by Cy¹ include piperidine and piperazine (e.g. piperidin-4-yl and piperazin-1-yl). Preferred optional substituents on the ring include those in which R²¹ and R²² independently represent C₁₋₄ alkyl, preferably substituted in the 4 position relative to the point of attachment to -(CH₂)_q-.

15

More preferred compounds of the invention include the compounds of Examples 1 to 74 described hereinafter.

Particularly preferred compounds of the invention include those in which:


- 20 R¹ represents H;
- R² represents H;
- R⁹ represents linear or branched C₂₋₇ alkyl, particularly linear C₃₋₆ alkyl and especially branched C₃₋₆ alkyl (e.g. *iso*-propyl, *iso*-butyl or *tert*-butyl);
- R¹⁰ represents -OH;
- 25 R¹¹ represents H;
- R¹² represents cyano, particularly in the *para* position relative to A;
- A represents a single bond or -CH₂O-;
- B represents -CH₂- or -(CH₂)₂-.

Preparation

According to the invention there is also provided a process for the preparation of compounds of formula I which comprises:

5

- (a) reaction of a compound of formula II,




10 wherein R¹, R², R¹⁰, R¹¹, R¹², A and B are as hereinbefore defined with a compound of formula III,




wherein L¹ represents a leaving group, such as Hal, imidazolyl or -OC(O)XR⁹, Hal represents Cl, Br or I, and R⁹ and X are as hereinbefore defined, for example at or above room temperature in the presence of a suitable base (e.g. aqueous NaOH, K₂CO₃ or TEA) and an appropriate organic solvent (e.g. DCM, THF, acetonitrile, toluene, or mixtures of such solvents);

20 (b) for compounds of formula I in which B represents CH₂ and R¹⁰ represents OH, reaction of a compound of formula IV,




wherein R^1 , R^2 , R^9 and X are as hereinbefore defined, with a compound of
5 formula V,




wherein R^{11} , R^{12} and A are as hereinbefore defined, for example at elevated
10 temperature (e.g. 60°C to reflux) in the presence of a suitable solvent (e.g.
a lower alkyl alcohol (e.g. IPA), acetonitrile, or a mixture of a lower alkyl
alcohol and water);

(c) reaction of a compound of formula IV, as hereinbefore defined, with a
15 compound of formula VI,



wherein L² represents a leaving group (e.g. mesylate, tosylate or Hal, where Hal is as hereinbefore defined) and R¹⁰, R¹¹, R¹², A and B are as hereinbefore defined, for example at elevated temperature (e.g. between 5 35°C and reflux temperature) in the presence of a suitable base (e.g. TEA or K₂CO₃) and an appropriate organic solvent (e.g. acetonitrile or DMSO);

(d) for compounds of formula I in which R¹¹ represents H, reduction of a 10 compound of formula VIII,




wherein R¹, R², R⁹, R¹², A, B and X are as hereinbefore defined, in the 15 presence of a suitable reducing agent and under appropriate reaction conditions; for example, for formation of compounds of formula I in which R¹⁰ represents OH, reduction may be performed under mild reaction conditions in the presence of e.g. sodium borohydride and an appropriate

12

organic solvent (e.g. THF); and for formation of compounds of formula I in which R¹⁰ represents H, reduction may be performed by activating the C=O group using an appropriate agent (such as tosylhydrazine) in the presence of a suitable reducing agent (e.g. sodium borohydride or sodium cyanoborohydride) and an appropriate organic solvent (e.g. a lower alkyl alcohol);

(e) for compounds of formula I in which R¹ and R² both represent H, reduction of a corresponding compound of formula IX,

10



wherein R⁹, R¹⁰, R¹¹, R¹², X, A and B are as hereinbefore defined, and in which the C=O group may be activated using an appropriate agent, such as tosylhydrazine, in the presence of a suitable reducing agent (e.g. sodium borohydride or sodium cyanoborohydride) and an appropriate organic solvent (e.g. a lower alkyl alcohol); when the C=O group is activated, the activation step may be carried out at between room and reflux temperature in the presence of an appropriate organic solvent (e.g. a lower alkyl alcohol such as methanol, ethanol or IPA), whereafter the reducing agent may be added to the reaction mixture and the reduction carried out at between 60°C


13

and reflux, advantageously in the presence of a suitable organic acid (e.g. acetic acid);

(f) for compounds of formula I in which R¹ and R² together represent -O(CH₂)₂O-, reaction of a corresponding compound of formula IX as hereinbefore defined with ethane-1,2-diol under appropriate reaction conditions, for example, provided that R⁹ does not represent *tert*-butyl, by refluxing in the presence of *p*TSA and an appropriate organic solvent (e.g. toluene), or, when R⁹ represents *tert*-butyl, under mild and/or non-acidic conditions such as those which are known to those skilled in the art;

(g) for compounds of formula I which are bispidine-nitrogen N-oxide derivatives, oxidation of the corresponding bispidine nitrogen of a corresponding compound of formula I, in the presence of a suitable oxidising agent (e.g. *m*CPBA), for example at 0°C in the presence of a suitable organic solvent (e.g. DCM);


(h) for compounds of formula I which are C₁₋₄ alkyl quaternary ammonium salt derivatives, in which the alkyl group is attached to a bispidine nitrogen, reaction, at the bispidine nitrogen, of a corresponding compound of formula I with a compound of formula XI,



XI


wherein R^b represents C₁₋₄ alkyl and Hal is as hereinbefore defined, for example at room temperature in the presence of an appropriate organic solvent (e.g. DMF), followed by purification (using e.g. HPLC) in the presence of a suitable counter-ion provider (e.g. NH₄OAc);

14
(i) for compounds of formula I in which R¹⁰ and R¹¹ represent H, B represents C₁₋₆ alkylene and A represents -N(R²⁰)(CH₂)_n-, reaction of a compound of formula XII,



5


wherein Ba represents C₁₋₆ alkylene and R¹, R², R⁹, R²⁰ and X are as hereinbefore defined with a compound of formula XIII,



10

wherein R¹², n and Hal are as hereinbefore defined, for example at 40°C in the presence of a suitable organic solvent (e.g. acetonitrile);

15
(j) reaction of a compound of formula II, as hereinbefore defined, with a compound of formula XIV,




wherein R⁹ and X are as hereinbefore defined, in the presence of 1,1'-carbonyldiimidazole, for example by refluxing in the presence of a suitable organic solvent (e.g. THF); or

15

(k) conversion of one R^{12} substituent to another using techniques well known to those skilled in the art.


Compounds of formula II may be prepared by reaction of a compound of
5 formula XV,



wherein R^1 and R^2 are as hereinbefore defined, with a compound of formula
10 VI as hereinbefore defined, for example as described hereinbefore for
synthesis of compounds of formula I (process step (c)), or, in the case of
compounds of formula II wherein B represents CH_2 and R^{10} represents OH,
with a compound of formula V as hereinbefore defined, for example as
described hereinbefore for synthesis of compounds of formula I (process
15 step (b)).

Compounds of formula II in which R^1 and R^2 both represent H may be
prepared by reduction of a compound of formula XVI,

16




wherein R¹⁰, R¹¹, R¹², A and B are as hereinbefore defined, and in which
 the C=O group may be activated using an appropriate agent, such as
 tosylhydrazine, for example as described hereinbefore for synthesis of
 5 compounds of formula I (process step (e)).

Compounds of formula IV may be prepared by reaction of a compound of
 formula XV, as hereinbefore defined, with a compound of formula III as
 hereinbefore defined, for example as described hereinbefore for synthesis of
 10 compounds of formula I (process step (a)).

Compounds of formula IV may alternatively be prepared by reaction of a
 compound of formula XV, as hereinbefore defined, with a compound of
 formula XIV, as hereinbefore defined, in the presence of 1,1'-
 15 carbonyldiimidazole, for example as described hereinbefore for synthesis of
 compounds of formula I (process step (j)).

Compounds of formula IV in which R¹ and R² represent H may alternatively
 be prepared by reduction of a corresponding compound of formula XVIII,

17




wherein R⁹ and X are as hereinbefore defined, and in which the C=O group may be activated using an appropriate agent, such as tosylhydrazine, for example as described hereinbefore for compounds of formula I (process step (e)).


Compounds of formula V may be prepared in accordance with techniques which are well known to those skilled in the art. For example, compounds of formula V in which:

- (1) A represents -CH₂O- may be prepared by reaction of a compound of formula XIX,

15




wherein R¹² is as hereinbefore defined, with a compound of formula XX,



wherein R¹¹ is as hereinbefore defined, for example at elevated temperature (between 60°C and reflux temperature) in the presence of a suitable base (e.g. K₂CO₃ or NaOH) and an appropriate organic solvent (e.g. acetonitrile or toluene water), or as otherwise described in the prior art;

(2) A represents -CH₂O- may be prepared by reaction of a compound of formula XIX, as hereinbefore defined, with a compound of formula XXI,


10



wherein R¹¹ is as hereinbefore defined, for example between room temperature and elevated temperature (e.g. 40°C) in the presence of a suitable base (e.g. K₂CO₃ or potassium ethoxide) and an appropriate organic solvent (e.g. acetonitrile or DMF);

(3) A represents a single bond and R¹¹ represents H may be prepared by reduction of a compound of formula XXII,

20




wherein R¹² is as hereinbefore defined, for example at between -15°C and room temperature in the presence of a suitable reducing agent (NaBH₄) and an appropriate organic solvent (e.g. THF), followed by elimination of

19

the resultant intermediate, for example at room temperature in the presence of a suitable base (e.g. K_2CO_3) and an appropriate organic solvent (e.g. acetonitrile); or


- 5 (4) A represents C_{1-4} alkylene, $-(CH_2)_nN(R^{20})-$, $-(CH_2)_nS(O)_2-$ or $-(CH_2)_nO-$ (in which latter three groups n represents 1, 2, 3 or 4) or $-(CH_2)_mC(H)(OH)(CH_2)_n-$ may be prepared by oxidation of a compound of formula XXIII,



- 10 in which A^a represents a single bond, C_{1-3} alkylene, $-(CH_2)_{n-1}N(R^{20})-$, $-(CH_2)_{n-1}S(O)_2-$ or $-(CH_2)_{n-1}O-$ (in which latter three groups n represents 1, 2, 3 or 4) or $-(CH_2)_{m-1}C(H)(OH)(CH_2)_n-$ (in which latter group n is as hereinbefore defined) and R^{20} and m are as hereinbefore defined, in the presence of a suitable oxidising agent (e.g. *m*CPBA), for example by refluxing in the presence of a suitable organic solvent (e.g. DCM).
- 15

Compounds of formula VI may be prepared by standard techniques. For example compounds of formula VI in which:


- 20 (1) A represents $-(CH_2)_nO-$ may be prepared by coupling a compound of formula XIX, as hereinbefore defined, to a compound of formula XXIV,




wherein L^4 represents a suitable leaving group (e.g. Hal) and Hal, n, R^{10} , R^{11} , B and L^2 are as hereinbefore defined;

20

(2) A represents $-C(O)N(R^{20})-$ may be prepared by coupling a compound of formula XXV,




wherein R¹² and R²⁰ are as hereinbefore defined, to a compound of formula XXVI,



wherein L⁴, R¹⁰, R¹¹, B and L² are as hereinbefore defined; or

(3) R¹⁰ represents -OH and R¹¹ represents methyl substituted by hydroxy, oxidation of a compound of formula XXVIA,




wherein R¹², A, B and L² are as hereinbefore defined,

in all three cases, under conditions which are well known to those skilled in the art (e.g. as described hereinafter).

Compounds of formula V and VI in which A represents $-(CH_2)_nS(O)-$ or $-(CH_2)_nS(O)_2-$ may be prepared by oxidation of a corresponding compound of formula I wherein A represents $-(CH_2)_nS-$, wherein n is as hereinbefore defined, in the presence of an appropriate amount of a suitable oxidising agent (e.g. *m*CPBA) and an appropriate organic solvent.

Compounds of formula VIII may be prepared in a similar fashion to compounds of formula I (see, for example, process steps (a) or (c)).


- 5 Alternatively, compounds of formula VIII in which B represents C₂ alkylene may be prepared by reaction of a compound of formula IV, as hereinbefore defined with a compound of formula XXVII,



- 10 wherein A and R¹² are as hereinbefore defined, for example a room temperature in the presence of a suitable organic solvent (e.g. ethanol).

- Compounds of formula XII may be prepared by removing an optionally substituted benzyloxycarbonyl unit from a corresponding compound of formula I in which R¹⁰ and R¹¹ both represent H and A represents
15 -N(R²⁰)C(O)O(CH₂)-, B represents B^a and B^a is as hereinbefore defined under conditions which are well known to those skilled in the art.

- Compounds of formula XV are known in the literature or are readily available using known techniques. For example, compounds of formula
20 XV in which R¹ and R², together with the carbon atom to which they are attached, represent -O-(CH₂)₂-O-, -(CH₂)₄- or -(CH₂)₅- may be prepared by reduction of a compound of formula XXVIII,




XXVIII

wherein R^{1a} and R^{2a}, together with the carbon atom to which they are attached, represent -O-(CH₂)₂-O-, -(CH₂)₄- or -(CH₂)₅-,
5 a suitable reducing agent (e.g. LiAlH₄) under conditions which are well known to those skilled in the art.

Compounds of formula IX may be prepared in analogous fashion to compounds of formula I. For example compounds of formula IX may be
10 prepared by reaction of a compound of formula XVI, as hereinbefore defined, and a compound of formula III, as hereinbefore defined, for example as described hereinbefore for synthesis of compounds of formula I (process step (a)).


15 Compounds of formulae IX, XVI and XVIII, may be prepared, advantageously, by reaction of (as appropriate) either (i) a compound of formula XXIX,



XXIX

23

wherein R⁹ and X are as hereinbefore defined, or (ii) 4-piperidone (or a protected derivative thereof), with (as appropriate) either (1) a compound of formula XXXI,




5

wherein R¹⁰, R¹¹, R¹², A and B are as hereinbefore defined, or (2) NH₃ (or a protected (e.g. benzyl) derivative thereof), in all cases in the presence of a formaldehyde (i.e. an appropriate source of formaldehyde, such as paraformaldehyde or formalin solution). The formation of compounds of formulae IX, XVI and XVIII may be carried out in this way for example at between room temperature and reflux (depending upon the concentration of the reactants) in the presence of an appropriate solvent (e.g. ethanol or methanol) and, preferably, in the presence of an organic acid (e.g. a C₁₋₆ carboxylic acid, especially acetic acid). We have advantageously found that this process may be used to prepare bispidine derivatives incorporating a carbamate group (-NC(O)XR⁹, where N is one of the bispidine nitrogens) directly from readily available starting materials, thus avoiding the need for long-winded, multi-step, syntheses, involving the coupling of a -C(O)XR⁹ group to a bispidine unit, following formation of the latter (as well as avoiding any further protection/deprotection steps which are necessary). It will be also appreciated by those skilled in the art that compounds of formula XV in which R¹ and R² both represent H may also be prepared via this method (i.e. by reaction of a compound of 4-piperidone (or a protected derivative thereof) with NH₃ (or a protected derivative thereof) in the

24

presence of a formaldehyde), provided that the intermediate so formed is subsequently reduced under appropriate reaction conditions.

Compounds of formula XXVIII may be prepared in accordance with
5 techniques which are well known to those skilled in the art. For example compounds of formula XXVIII in which R^{1a} and R^{2a} together represent -(CH₂)₄- or -(CH₂)₅- may be prepared by reaction of a compound of formula XXXII,



10 wherein R^{1a'} and R^{2a'} together represent -(CH₂)₄- or -(CH₂)₅-, with a mixture with a mixture of phosphoric acid and sulfuric acid, for example at 120°C.

Compounds of formula XXXI are well known in the literature or are
15 readily available using known techniques. For example, compounds of formula XXXI wherein R¹⁰ represents OH, R¹¹ represents H and B represents CH₂ may be prepared by reaction of a compound of formula V in which R¹¹ represents H with ammonium hydroxide under conditions which are well known to those skilled in the art.

20

Compounds of formulae III, XI, XIII, XIV, XIX, XX, XXI, XXII, XXIII, XXIV, XXV, XXVI, XXVIA, XXVII, XXIX and XXXII, and derivatives thereof, are either commercially available, are known in the literature, or may be obtained either by analogy with the processes described herein, or
25 by conventional synthetic procedures, in accordance with standard

25

techniques, from readily available starting materials using appropriate reagents and reaction conditions.

Substituents on the aryl (e.g. phenyl), and (if appropriate) heterocyclic, group(s) in compounds of formulae I, II, III, IV, V, VI, VIII, IX, XII, XIII, XIV, XVI, XVIII, XIX, XXII, XXIII, XXV, XXVIA, XXVII, XXIX and XXXI may be converted to other claimed substituents using techniques well known to those skilled in the art. For example, nitrobenzene may be reduced to an aminobenzene, hydroxy may be converted to alkoxy, alkoxy may be hydrolysed to hydroxy etc.

The compounds of the invention may be isolated from their reaction mixtures using conventional techniques.

It will be appreciated by those skilled in the art that, in the process described above, the functional groups of intermediate compounds may be, or may need to be, protected by protecting groups.

Functional groups which it is desirable to protect include hydroxy, amino and carboxylic acid. Suitable protecting groups for hydroxy include trialkylsilyl and diarylalkylsilyl groups (e.g. *tert*-butyldimethylsilyl, *tert*-butyldiphenylsilyl or trimethylsilyl), tetrahydropyranyl and alkylcarbonyloxy groups (e.g. methyl- and ethylcarbonyloxy groups). Suitable protecting groups for amino include benzyl, *tert*-butyloxycarbonyl, 9-fluorenylmethoxycarbonyl or benzyloxycarbonyl. Suitable protecting groups for carboxylic acid include C₁₋₆ alkyl or benzyl esters.

The protection and deprotection of functional groups may take place before or after any of the reaction steps described hereinbefore.

Protecting groups may be removed in accordance with techniques which are well known to those skilled in the art and as described hereinafter.

- 5 Many protected derivatives of the intermediate compounds described hereinbefore are commercially available.

The use of protecting groups is fully described in "Protective Groups in Organic Chemistry", edited by J W F McOmie, Plenum Press (1973), and
10 "Protective Groups in Organic Synthesis", 2nd edition, T W Greene & P G M Wutz, Wiley-Interscience (1991).

Persons skilled in the art will appreciate that, in order to obtain compounds of the invention in an alternative, and, on some occasions, more convenient,
15 manner, the individual process steps mentioned herein may be performed in a different order, and/or the individual reactions may be performed at a different stage in the overall route (i.e. substituents may be added to and/or chemical transformations performed upon, different intermediates to those associated hereinbefore with a particular reaction). This will depend *inter alia* on factors such as the nature of other functional groups present in a particular substrate, the availability of key intermediates and the protecting group strategy (if any) to be adopted. Clearly, the type of chemistry involved will influence the choice of reagent that is used in the said synthetic steps, the need, and type, of protecting groups that are employed,
20 and the sequence for accomplishing the synthesis.

It will also be appreciated by those skilled in the art that, although certain protected derivatives of compounds of formula I, which may be made prior to a final deprotection stage, may not possess pharmacological activity as

27

such, they may be administered parenterally or orally and thereafter metabolised in the body to form compounds of the invention which are pharmacologically active. Such derivatives may therefore be described as "prodrugs". Moreover, we have found that certain compounds of formula I
5 may act as prodrugs of other compounds of formula I.

All prodrugs of compounds of formula I are included within the scope of the invention.

10 Some of the intermediates referred to hereinbefore are novel. According to a further aspect of the invention there is thus provided: (a) a novel compound of formula IV as hereinbefore defined or a protected derivative thereof; (b) a novel compound of formula IX as hereinbefore defined or a protected derivative thereof; (c) a novel compound of formula XVI as
15 hereinbefore defined or a protected derivative thereof; and (d) a novel compound of formula XVIII as hereinbefore defined or a protected derivative thereof.

Medical and pharmaceutical use

20

The compounds of the invention are useful because they possess pharmacological activity. They are therefore indicated as pharmaceuticals.

Thus, according to a further aspect of the invention there is provided the
25 compounds of the invention for use as pharmaceuticals.

In particular, the compounds of the invention exhibit myocardial electrophysiological activity, for example as demonstrated in the test described below.

- 5 The compounds of the invention are thus expected to be useful in both the prophylaxis and the treatment of arrhythmias, and in particular atrial and ventricular arrhythmias.

The compounds of the invention are thus indicated in the treatment or
10 prophylaxis of cardiac diseases, or in indications related to cardiac diseases, in which arrhythmias are believed to play a major role, including ischaemic heart disease, sudden heart attack, myocardial infarction, heart failure, cardiac surgery and thromboembolic events.

- 15 In the treatment of arrhythmias, compounds of the invention have been found to selectively delay cardiac repolarization, thus prolonging the QT interval, and, in particular, to exhibit class III activity. Although compounds of the invention have been found to exhibit class III activity in particular, in the treatment of arrhythmias, their mode(s) of activity is/are not necessarily
20 restricted to this class.

Compounds of the invention have also been found to be potent, yet possess a duration of action which is relatively short (e.g. 1 to 120, preferably 1 to 60, more preferably 1 to 30 and particularly 1 to 15 minutes, as measured in
25 the test described below) when compared to compounds known in the prior art. Compounds of the invention are therefore expected to possess the advantages hereinbefore mentioned for short acting compounds.

According to a further aspect of the invention, there is provided a method of treatment of an arrhythmia which method comprises administration of a therapeutically effective amount of a compound of the invention to a person suffering from, or susceptible to, such a condition.

Pharmaceutical preparations

The compounds of the invention will normally be administered subcutaneously, intravenously, intraarterially, transdermally, intranasally, by inhalation, or by any other parenteral route, in the form of pharmaceutical preparations comprising the active ingredient either as a free base, a pharmaceutical acceptable ion exchanger or a non-toxic organic or inorganic acid addition salt, in a pharmaceutically acceptable dosage form. Depending upon the disorder and patient to be treated, as well as the route of administration, the compositions may be administered at varying doses.

The compounds of the invention may also be combined with any other drugs useful in the treatment of arrhythmias and/or other cardiovascular disorders.

According to a further aspect of the invention there is thus provided a pharmaceutical formulation including a compound of the invention in admixture with a pharmaceutically acceptable adjuvant, diluent or carrier.

30

Suitable daily doses of the compounds of the invention in therapeutic treatment of humans are about 0.05 to 5.0 mg/kg body weight at parenteral administration.

- 5 The compounds of the invention have the advantage that they are effective against cardiac arrhythmias.

Compounds of the invention have also been found to possess a shorter duration of action than compounds known in the prior art and are
10 therefore expected to be particularly useful when used in the acute conversion of arrhythmias as mentioned hereinbefore.

Compounds of the invention may also have the advantage that they may be more efficacious than, be less toxic than, have a broader range of activity
15 (including exhibiting any combination of class I, class II, class III and/or class IV activity (especially class I, class II and/or class IV activity in addition to class III activity)) than, be more potent than, produce fewer side effects (including a lower incidence of proarrhythmias such as *torsades de pointes*) than, be more easily absorbed than, or that they may
20 have other useful pharmacological properties over, compounds known in the prior art.

Biological TestsTest APrimary Electrophysiological Effects In Anaesthetised Guinea Pigs

- 5 Guinea pigs weighing between 660 an 1100 g were used. The animals were housed for at least one week before the experiment and had free access to food and tap water during that period.

Anaesthesia was induced by an intraperitoneal injection of pentobarbital (40
10 to 50 mg/kg) and catheters were introduced into one carotid artery (for blood pressure recording and blood sampling) and into one jugular vein (for drug infusions). Needle electrodes were placed on the limbs for recording of ECGs (lead II). A thermistor was placed in the rectum and the animal was placed on a heating pad, set to a rectal temperature of between 37.5 and
15 38.5°C.

A tracheotomy was performed and the animal was artificially ventilated with room air by use of a small animal ventilator, set to keep blood gases within the normal range for the species. In order to reduce autonomic influences
20 both vagi were cut in the neck, and 0.5 mg/kg of propranolol was given intravenously, 15 minutes before the start of the experiment.

The left ventricular epicardium was exposed by a left-sided thoracotomy, and a custom-designed suction electrode for recording of the monophasic action potential (MAP) was applied to the left ventricular free wall. The electrode was kept in position as long as an acceptable signal could be recorded, otherwise it was moved to a new position. A bipolar electrode for pacing was clipped to the left atrium. Pacing (2 ms duration, twice the

32

diastolic threshold) was performed with a custom-made constant current stimulator. The heart was paced at a frequency just above the normal sinus rate during 1 minute every fifth minute throughout the study.

- 5 The blood pressure, the MAP signal and the lead II ECG were recorded on a Mingograph ink-jet recorder (Siemens-Elema, Sweden). All signals were collected (sampling frequency 1000 Hz) on a PC during the last 10 seconds of each pacing sequence and the last 10 seconds of the following minute of sinus rhythm. The signals were processed using a custom-made program
10 developed for acquisition and analysis of physiological signals measured in experimental animals (see Axenborg and Hirsch, Comput. Methods Programs Biomed. 41, 55 (1993)).

The test procedure consisted of taking two basal control recordings, 5
15 minutes apart, during both pacing and sinus rhythm. After the second control recording, the first dose of the test substance was infused in a volume of 0.2 mL into the jugular vein catheter for 30 seconds. Three minutes later, pacing was started and a new recording was made. Five minutes after the previous dose, the next dose of test substance was
20 administered. Six to ten consecutive doses were given during each experiment.

Data analysis

- 25 Of the numerous variables measured in this analysis, three were selected as the most important for comparison and selection of active compounds. The three variables selected were the MAP duration at 75 percent repolarization during pacing, the atrio-ventricular (AV) conduction time (defined as the interval between the atrial pace pulse and the start of the ventricular MAP)

33

during pacing, and the heart rate (defined as the RR interval during sinus rhythm). Systolic and diastolic blood pressure were measured in order to judge the haemodynamic status of the anaesthetised animal. Further, the ECG was checked for arrhythmias and/or morphological changes.

5

The mean of the two control recordings was set to zero and the effects recorded after consecutive doses of test substance were expressed as percentage changes from this value. By plotting these percentage values against the cumulative dose administered before each recording, it was 10 possible to construct dose-response curves. In this way, each experiment generated three dose-response curves, one for MAP duration, one for AV-conduction time and one for the sinus frequency (RR interval). A mean curve of all experiments performed with a test substance was calculated, and potency values were derived from the mean curve. All dose-response 15 curves in these experiments were constructed by linear connection of the data points obtained. The cumulative dose prolonging the MAP duration by 10% from the baseline was used as an index to assess the class III electrophysiological potency of the agent under investigation (D_{10}).

20 Test BMetabolic Stability of Test Compounds

An *in vitro* screen was set up to determine the metabolic stability of the compounds of the invention.

25

The hepatic S-9 fraction from dog, man, rabbit and rat with NADPH as co-factor was used. The assay conditions were as follows: S-9 (3 mg/mL), NADPH (0.83 mM), Tris-HCl buffer (50 mM) at pH 7.4 and 10 μ M of test compound.

The reaction was started by addition of test compound and terminated after 0, 1, 5, 15 and 30 minutes by raising the pH in the sample to above 10 (NaOH; 1 mM). After solvent extraction, the concentration of test 5 compound was measured against an internal standard by LC (fluorescence/UV detection).

The percentage of test compound remaining after 30 minutes (and thus $t_{1/2}$) were calculated and used as a measure for metabolic stability.

10

The invention is illustrated by way of the following examples.

Examples

15 General Experimental Procedures

Mass spectra were recorded on a Finnigan MAT TSQ 700 triple quadrupole mass spectrometer equipped with an electrospray interface (FAB-MS) and VG Platform II mass spectrometer equipped with an electrospray interface (LC-MS), a Hewlett Packard model 6890 gas chromatograph connected to a 20 Hewlett-Packard model 5973A mass spectrometer *via* a Hewlett Packard HP-5-MS GC column, or a Shimadzu QP-5000 GC/mass spectrometer (CI, methane). ^1H NMR and ^{13}C NMR measurements were performed on a BRUKER ACP 300 and Varian UNITY plus 400 and 500 spectrometers, operating at ^1H frequencies of 300, 400 and 500 MHz respectively, and at 25 ^{13}C frequencies of 75.5, 100.6 and 125.7 MHz respectively. Alternatively, ^{13}C NMR measurements were performed on a BRUKER ACE 200 spectrometer at a frequency of 50.3 MHz.

11 U -12- 1998

35

Rotamers may or may not be denoted in spectra depending upon ease of interpretation of spectra. Unless otherwise stated, chemical shifts are given in ppm with the solvent as internal standard.

5 Synthesis of intermediates

Example A

4-(2-Oxiranylmethoxy)benzonitrile

Epichlorohydrin (800 mL) and K_2CO_3 (414 g) were added to a stirred 10 solution of *p*-cyanophenol (238 g) in 2.0 L MeCN and the reaction mixture was refluxed under inert atmosphere for 2 h. The hot solution was filtered and the filtrate concentrated giving a clear oil which was crystallized from di-*iso*-propyl ether giving the product in 75% yield.

15 ^{13}C NMR ($CDCl_3$): δ 44.4, 49.7, 69.0, 104.5, 115.3, 118.9, 134.0, 161.6

Example B

2-{[(3-Nitrophenyl)sulfonyloxy]methyl}oxirane

m-Nitrobenzenesulfonylchloride (12.6 g; 57 mmol) was added to a cold 20 (-20°C) solution of (*R*)-(+)glycidol (5.5 g; 74 mmol) and TEA (10.3 mL; 74 mmol). The reaction mixture was stirred at -20°C for 96 h. The solution was filtered and the filtrate washed with tartaric acid (10% w/w), brine, H_2O and concentrated giving the title compound in a 97% yield.

25 1H NMR ($CDCl_3$): δ 2.62 (dd, 1H), 2.84 (dd, 1H), 3.22 (m, 1H), 4.07 (dd, 1H), 4.49 (dd, 1H), 7.80 (t, 1H), 8.25 (m, 1H), 8.52 (m, 1H), 8.78 (m, 1H)

Example C4-[*(2S*)-Oxiranylmethoxy]benzonitrile

The title compound was prepared in a 90% yield according to the procedure described in Example A above starting from (*R*)-(-)-epichlorohydrin.

Example D4-[*(2R*)-Oxiranylmethoxy]benzonitrile

The title compound was prepared according to the procedure described in Example A above starting from (*S*)-(-)-epichlorohydrin.

[α]_D²⁰ = -14.1° (c = 1.0; acetone)

¹H NMR (CDCl₃): δ 2.79 (1H, m); 2.98 (1H, m); 3.39 (1H, m); 3.98 (1H, m); 4.37 (1H, m); 6.99 (2H, d); 7.60 (2H, d)

15

Example E3-Benzyl-3,7-diazabicyclo[3.3.1]nonane(a) 3,7-Dibenzyl-3,7-diazabicyclo[3.3.1]nonane

20 The sub-title compound was prepared according to the method described in J. Org. Chem. 41, 1593, (1976) except that 3,7-dibenzyl-3,7-diazabicyclo[3.3.1]nonan-9-one (also prepared according to the method described in J. Org. Chem. 41, 1593 (1976)) was used instead of *N*-benzyl-*N*-methylbispidone.

25

(b) 3-Benzyl-3,7-diazabicyclo[3.3.1]nonane

3,7-Dibenzyl-3,7-diazabicyclo[3.3.1]nonane (1.97 g; 6.4 mmol; from step (a) above) was dissolved in EtOH (95%) and hydrogenated over 5% Pd/C at 1 atm. until tlc indicated that the reaction was complete. The catalyst

37

was removed by filtration through a pad of celite and the residue was concentrated under reduced pressure to give the title compound in a quantitative yield.

5 ^{13}C NMR (CDCl_3): δ 30.1, 33.4, 36.0, 52.5, 59.6, 64.3, 126.9, 128.3,
128.7, 138.8

Example F

tert-Butyl 3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

10

(a) tert-Butyl 7-benzyl-9-oxy-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

Paraformaldehyde (4.00 g; 127 mmol) was added to a solution of benzylamine (13.7 g; 126 mmol) in ethanol (190 mL). The solution was heated to 60°C and a solution of acetic acid (15.2 g; 252 mmol) in ethanol (160 mL) was added over 2 hours. After additional stirring for 1 hour, the solution was cooled to room temperature. This solution was added (over 2 hours) to a mixture of 1-*tert*-butoxycarbonyl-4-piperidone (25.5 g; 127 mmol) and paraformaldehyde (4.80 g; 152 mmol) in ethanol (270 mL) which had been heated to 60°C. After reflux overnight, the solution was cooled to room temperature. The ethanol was removed by evaporation. Extractive work-up was performed in toluene:water and the material was filtered through silica in a toluene:ethyl acetate system. Evaporation of the eluate gave a solid material (37.4 g). The purity was 90 area% (HPLC) and the yield was 60%. By performing a crystallisation in *iso*-propanol, a compound with a purity of 98 area% (HPLC) and a yield of 70% was obtained.

MS (EI; 70 eV): m/z 91 (100%), m/z 57 (42%), m/z 273 (32%), m/z 330 (5%)

38

¹³C NMR (CDCl₃): δ 28.72, 47.71, 49.91, 50.60, 58.83, 59.16, 61.96, 80.18, 127.37, 128.45, 128.89, 137.57, 154.89, 213.66 ppm using TMS as reference.

5 (b) tert-Butyl 7-benzyl-9-oxy-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate
(alternative preparation)

Benzylamine (6.51 g; 60.2 mmol), acetic acid (72.3 g, 1200 mmol), paraformaldehyde (3.71 g; 120 mmol) and 1-*tert*-butoxycarbonyl-4-piperidone (12.0 g; 60.2 mmol), were added to ethanol (300 mL). The solution was heated to 65°C and stirred at this temperature for 2 hours. The same work-up procedure as that described in step (a) above was performed, yielding 15.78 g of material with a purity of 92 area% (HPLC) and a yield of 70%. Recrystallisation from *iso*-propanol yielded a compound with a purity of 94 area% (HPLC) in a yield of 54%.

15

(c) tert-Butyl 7-benzyl-3,7-diazabicyclo[3.3.1]-nonane-3-carboxylate

A mixture of 4-toluenesulfonehydrazide (12.4 mmol; 2.30 g) and *tert*-butyl 7-benzyl-9-oxy-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (10.1 mmol; 4.00 g; 83.3%; from step (a) above) were dissolved in isopropanol (30 mL) and heated at reflux for 2 hours. Acetic acid (2.5 mmol; 0.15 g) and sodium cyanoborohydride (12.1 mmol, 0.76 g) were added and the mixture was again heated at reflux for 2 hours. The slurry was cooled to ambient temperature and filtered. The filtrate was concentrated and an extractive work-up was performed in toluene:water. The toluene solution was concentrated to give 0.95 g of sub-title compound, with a purity of 90 area% (GC) in a yield of 60%.

MS (EI; 70 eV): m/z 259 (100%), m/z 91 (95%), m/z 169 (45%), m/z 57 (35%), m/z 316 (25%)

39

^{13}C NMR (CDCl_3): δ 28.67, 28.95, 31.11, 47.55, 48.38, 58.70, 58.96, 63.46, 78.71, 126.57, 128.00, 128.53, 138.94, 155.20 ppm using TMS as a reference

5 (d) tert-Butyl 3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

tert-Butyl 7-benzyl-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (from step (c) above) was debenzylated according to the method described in Example E(b) above to give the title compound in quantitative yield.

10 ^{13}C NMR (CDCl_3): δ 28.05, 28.29, 31.33, 48.35, 49.11, 51.53, 79.34, 155.16

Example G

4-[3-(3,7-Diazabicyclo[3.3.1]non-3-yl)-2-hydroxypropoxy]benzonitrile

15 HCl-saturated EtOAc (600 mL) was added to a solution of *tert*-butyl 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (62 g; see Example 2 below) in EtOAc (600 mL) and the mixture was stirred at rt. for 4 h. The solvent was removed under reduced pressure, the residue was dissolved in MeCN (1.3 L) and K_2CO_3 (100 g) was added. The suspension was stirred for 12 h and filtered. Concentration of the filtrate gave the title compound in a 90% yield.

20 ^{13}C NMR (CDCl_3): δ 28.9, 29.2, 32.3, 50.9, 57.7, 60.8, 62.1, 66.0, 71.2, 104.0, 115.3, 119.1, 133.9, 162.1

25

(The title compound was also readily converted to the hydrochloride salt (also used as an intermediate in the examples below) using standard techniques.)

Example H*iso*-Propyl 3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

(a) *iso*-Propyl 7-benzyl-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

5 NaOH (6.0 mL; 10M), H₂O (10 mL) and *iso*-propylchloroformate (55 mmol) were added to a solution of 3-benzyl-3,7-diazabicyclo[3.3.1]nonane (10.8 g; 50 mmol; see Example E above) in DCM (50 mL). The reaction mixture was stirred for 3 h and the phases were then separated. The organic phase was washed with H₂O and brine, dried and concentrated to give the sub-title compound in a 95% yield.

10
(b) *iso*-Propyl 3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

The title compound was prepared according to the method described in Example E(b) above from *iso*-propyl 7-benzyl-3,7-diazabicyclo-[3.3.1]nonane-3-carboxylate (from step (a) above).

FAB-MS (M + 1)⁺ 213 (m/z)

¹³C NMR (CD₃CN): δ 22.53, 29.34, 32.23, 49.46, 52.40, 68.67, 156.24

20 Example I

tert-Butyl 9-oxy-3,7-diazabicyclo[3.3.1]-nonan-3-carboxylate

tert-Butyl 7-benzyl-9-oxy-3,7-diazabicyclo[3.3.1]-nonan-3-carboxylate (1.2 g; 3.17 mmol) and palladium on charcoal paste (0.10 g; 5% Pd/C; 63% water) were added to ethanol (20 mL). The hydrogenolysis was performed by applying a pressure of 4 bars of hydrogen. After the reaction was completed, the suspension was filtered, concentrated and purified with flash chromatography, yielding 0.20 g of material with a purity of 93 area% (GC).

41

MS (EI; 70 eV): m/z 57 (100%), m/z 96 (80%), m/z 41 (40%), m/z 140 (35%), m/z 110 (30%), m/z 183 (30%), m/z 240 (15%)
¹³C NMR (CDCl₃): δ 28.52, 49.36, 50.48, 55.48, 80.96, 154.87, 213.41 ppm using TMS as a reference

5

Example J

Ethyl 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-9-oxy-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

10 (a) 3-(4-Cyanophenoxy)-2-hydroxypropylamine

IPA (300 mL) was added to a stirred suspension of 4-(2-oxiranylmethoxy)benzonitrile (100 g; 571 mmol; see Example A above) in NH₃ (500 mL; conc.), and the reaction mixture was stirred at rt. for 3 days. The precipitate was filtered off and the residue concentrated and recrystallized from MeCN to give the sub-title compound in a 46% yield.

(b) Ethyl 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-9-oxy-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

A solution of AcOH (0.30 g; 5.0 mmol) in MeOH (5 mL), followed by paraformaldehyde (0.33 g; 11.0 mmol), were added to a stirred suspension of 3-(4-cyanophenoxy)-2-hydroxypropylamine (0.96 g; 5.0 mmol; from step (a) above) in MeOH (5 mL) under inert atmosphere (N₂). The temperature was raised to 55°C and a solution of 1-ethoxycarbonyl-4-piperidone (0.86 g; 5.0 mmol) in MeOH (5 mL) was added and the reaction mixture stirred for 6 h. The solids were filtered off and the solution was concentrated. The solid residue was partitioned between water and diethyl ether. The aqueous phase was collected and the pH adjusted to 10 (4M NaOH) and extracted with DCM. The combined organic layers were concentrated and purified using column

42

chromatography (DCM:MeOH; 19:1) to give the sub-title compound in a 30% yield.

13C NMR (CDCl₃): δ 14.5, 48.0, 50.6, 57.3, 61.2, 62.2, 65.4, 70.3,
5 104.2, 115.3, 119.0, 133.9, 157.9, 161.9, 211.7

Preparation of Compounds of Formula I

Example 1

10 Ethyl 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-3,7-diazabicyclo[3.3.1]-nonane-3-carboxylate

Ethylchloroformate (930 mg; 8.4 mmol) was added to a stirred solution of 4-[3-(3,7-diazabicyclo[3.3.1]non-3-yl)-2-hydroxypropoxy]benzonitrile (2.3 g; 7.6 mmol; see Example G above) and NaOH (1.5 mL; 10 M) in DCM (60 mL). The solution was stirred at rt. for 1 h, washed with water and the organic layer was separated, dried (Na₂SO₄) and concentrated. Purification using column chromatography (DCM:MeOH; 19:1) gave the title compound (1.4 g).

20 ¹³C NMR (CDCl₃): δ 14.7, 29.2, 32.7, 48.6, 56.7, 60.2, 61.3, 62.6, 65.0, 70.8, 104.0, 115.4, 129.8, 133.9, 157.6, 162.2

Example 2

25 tert-Butyl 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-3,7-diazabicyclo-[3.3.1]nonane-3-carboxylate

A mixture of *tert*-butyl 3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (2.3 g; 10 mmol; see Example F above) and 4-(2-oxiranylmethoxy)benzonitrile (1.8 g; 10 mmol; see Example A above) in IPA (10 mL) and H₂O (1 mL) was stirred at 60°C for 12 h. The reaction mixture was concentrated under

43

reduced pressure and the residue dissolved in DCM and washed with brine, H₂O, dried and concentrated. Purification using column chromatography (DCM:MeOH; 19:1) gave the title compound in a 81% yield.

5

¹³C NMR (CDCl₃): δ 28.44, 28.77, 29.33, 31.93, 47.53, 49.34, 56.87, 60.14, 61.60, 65.03, 70.70, 79.37, 103.85, 115.32, 119.13, 133.79, 155.91, 162.16

10 Example 33,7-Diazabicyclo[3.3.1]nonane-3-carboxylic acid, 7-[(2S)-3-(4-cyano-phenoxy)-2-hydroxypropyl]-1,1-dimethylethyl ester

4-[(2S)-Oxiranylmethoxy]benzonitrile (5.19 g; 29.6 mmol; see Example C above) was added to a stirred solution of *tert*-butyl 3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (6.7 g; 29.6 mmol; see Example F above) in IPA (30 mL) and H₂O (3 mL). The reaction mixture was stirred at 60°C for 12 h and then at rt. for 48 h. The reaction mixture was concentrated, the residue dissolved in DCM, dried (MgSO₄) and concentrated. The residue was purified using column chromatography (hexane:EtOAc:MeOH; 50:45:5) to give the title product as a white foam in a 56% yield (6.65 g).

[α]₂₀^D = 16 (c=1.0; MeOH).

ESI-MS (M + 1)⁺ 402 (m/z)

25 ¹³C NMR (CDCl₃): δ 28.44, 28.77, 29.33, 31.93, 47.53, 49.34, 56.87, 60.14, 61.60, 65.03, 70.70, 79.37, 103.85, 115.32, 119.13, 133.79, 155.91, 162.16

Example 4*tert*-Butyl 7-[(2*R*)-3-(4-cyanophenoxy)-2-hydroxypropyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

5 The title compound was prepared analogously to the method described in Example 3 above from 4-[(2*R*)-oxiranylmethoxy]benzonitrile (0.98 g; 5.59 mmol; see Example D above) and *tert*-butyl 3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (1.26 g; 5.59 mmol; see Example F above). After the reaction was complete, the residue was
10 dissolved in DCM and washed with brine, separated, dried (Na_2SO_4) and concentrated. The residue was dissolved in MeOH (10 mL) and 1 eq. tartaric acid was added. Freeze-drying gave the product as the corresponding tartaric acid salt in 88% yield (2.7 g).

15 ^{13}C NMR (CDCl_3): δ 28.44, 28.77, 29.33, 31.93, 47.53, 49.34, 56.87, 60.14, 61.60, 65.03, 70.70, 79.37, 103.85, 115.32, 119.13, 133.79, 155.91, 162.16

Example 5*iso*-Propyl 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

Prepared according to the method described in Example 1 above, starting with *iso*-propylchloroformate.

25 ESI-MS ($M + 1$)⁺ 388 (m/z)

^{13}C NMR (CDCl_3): δ 22.38, 29.22, 29.49, 32.82, 48.49, 49.43, 56.46, 60.09, 62.47, 64.85, 68.38, 70.83, 103.96, 115.33, 119.26, 133.90, 157.32, 162.20

Example 6tert-Pentyl 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-3,7-diazabicyclo-[3.3.1]nonane-3-carboxylate

5

(a) tert-Pentyl 7-benzyl-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

Di-*tert*-pentyl dicarbonate (6.1 mL; 25 mmol) was added to a stirred solution of 3-benzyl-3,7-diazabicyclo[3.3.1]nonane (5.41 g; 25 mmol; see Example E above) in THF (50 mL). The reaction mixture was stirred 12 h at rt. and the solvent evaporated.

(b) tert-Pentyl 3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

tert-Pentyl 7-benzyl-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (8.67 g; from step (a) above) was dissolved in EtOH (45 mL) and hydrogenated over 5% Pd/C at 1 atm. for 10 h. The catalyst was removed by filtration and the residue was concentrated giving the sub-title compound.

(c) tert-Pentyl 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-3,7-diazabicyclo-[3.3.1]nonane-3-carboxylate

tert-Pentyl 3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (1.0 g; 4.16 mmol; from step (b) above) was dissolved in IPA:H₂O (9:1; 4 mL) and 4-(2-oxiranylmethoxy)benzonitrile (1.46 g; 8.32 mmol; see Example A above) was added to the resultant solution. The reaction mixture was stirred at 60°C for 3 h, concentrated and the residue subjected to column chromatography (DCM:MeOH; gradient 1:0 to 68:32) giving the title compound (1.45 g).

¹³C NMR (CDCl₃): δ 8.2, 25.8, 28.6, 31.8, 33.8, 47.4, 49.2, 56.6, 59.9, 61.3, 64.8, 70.6, 81.5, 103.6, 115.2, 119.0, 133.6, 155.7, 162.0

Example 7Isopropyl 7-[(2*S*)-3-(4-cyanophenoxy)-2-hydroxypropyl]-3,7-diazabicyclo-[3.3.1]nonane-3-carboxylate

- 5 The title compound was prepared according to the method described in Example 3 above, using *iso*-propyl 3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (see Example H above). The yield was 90%.

ESI-MS (M + 1)⁺ 388 (m/z)

10 ¹³C NMR (CDCl₃): δ 22.13, 22.20, 29.06, 29.31, 32.59, 48.30, 49.23, 56.34, 59.90, 62.24, 64.74, 68.14, 70.72, 103.74, 115.20, 119.02, 133.68, 157.07, 162.07

Example 8

- 15 *iso*-Butyl 7-[(3-(4-cyanophenoxy)-2-hydroxypropyl]-3,7-diazabicyclo-[3.3.1]nonane-3-carboxylate

The title compound is prepared according to the method described in Example 47 below, using *iso*-butylchloroformate and 1.5 eq. of K₂CO₃ as base.

20

ESI-MS (M + 1)⁺ 402 (m/z)

¹³C NMR (CDCl₃): δ 19.09, 19.22, 27.84, 29.17, 29.34, 32.69, 48.33, 49.35, 56.48, 60.05, 62.36, 64.90, 70.85, 71.55, 103.71, 115.34, 119.16, 133.79, 157.67, 162.19

25

Example 9Cyclopentyl 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

The title compound was prepared according to the method described in
5 Example 1 above, using cyclopentylchloroformate.

FAB-MS ($M + 1$)⁺ 414 (m/z)

¹³C NMR (CD₃OD; 55°C): δ 23.56, 23.70, 29.18, 29.46, 32.70, 32.95,
33.42, 48.28, 49.50, 56.35, 60.09, 62.38, 64.94, 70.84, 77.86, 103.92,
10 115.32, 119.32, 133.65, 157.44, 162.21

Example 10tert-Butyl 7-{3-[(4-cyano-2-(cyclopropylcarbamoyl)phenoxy]-2-hydroxypropyl}-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

15

(a) Methyl 5-bromo-2-hydroxybenzoate

Br₂ (52 g) was slowly added to a stirred solution of methyl salicylate (50 g; 330 mmol) in 300 mL acetic acid. The reaction mixture was stirred at rt. for 10 h, poured on ice-water and the precipitate recrystallized from
20 MeOH, giving the sub-title compound in a 83% yield.

(b) Methyl 5-cyano-2-hydroxybenzoate

Methyl 5-bromo-2-hydroxybenzoate (190.8 g; from step (a) above) and CuCN (73.9 g) were refluxed in DMF (500 mL) for 7 h. The temperature
25 was allowed to decrease to 80°C and HCl (500 mL) and FeCl₃ (165.0 g) were added. The reaction mixture was stirred for 30 min., concentrated and partitioned between H₂O and DCM. The organic layer was dried, concentrated the residue recrystallized from methylethyl ketone giving the sub-title compound in a 61 % yield.

(c) *N¹-Cyclopropyl-5-cyano-2-hydroxybenzamide*

Cyclopropyl amine (14.3 g) and Na (100 mg) were added to a solution of methyl 5-cyano-2-hydroxybenzoate (10.0 g; from step (b) above) in 5 DMSO (40 mL). The reaction mixture was heated at 80°C in a sealed steel vessel overnight, diluted with H₂O, acidified and extracted with EtOAc giving the sub-title compound (11.0 g), after concentration of the organic layer.

10 (d) *N¹-Cyclopropyl-5-cyano-2(2-oxiranylmethoxy)benzamide*

The sub-title compound was prepared according to the method described in Example A above from *N¹-cyclopropyl-5-cyano-2-hydroxybenzamide* (from step (c) above).

15 (e) *tert-Butyl 7-{3-[4-cyano-2-(cyclopropylcarbamoyl)phenoxy]-2-hydroxypropyl}-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate*

The title compound was prepared according to the method described in Example 2 above from *N¹-cyclopropyl-5-cyano-2(2-oxiranylmethoxy)-benzamide* (from step (d) above).

20

¹³C NMR (CDCl₃): δ 6.5, 23.0, 28.0, 31.5, 47.5, 49.0, 57.0, 61.5, 72.0, 79.5, 105.0, 113.0, 118.0, 123.0, 136.0, 156.5, 159.0, 164.0

Example 11*tert*-Butyl 7-{3-[*(4*-cyano-2-(*iso*-propylcarbamoyl)phenoxy]-2-hydroxpropyl}-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate5 (a) *N*¹-*iso*-Propyl-5-cyano-2-hydroxybenzamide

Methyl 5-cyano-2-hydroxybenzoate (8.85 g; 50 mmol; see Example 10(b) above) and NaCN (250 mg; 5 mmol) were dissolved in DMSO (10 mL) and MeOH (50 mL) and *iso*-propyl amine (25 mL) was added. The reaction mixture was heated (60°C) in a sealed steel vessel for 10 h, the 10 MeOH was removed under reduced pressure and H₂O (500 mL) was added. The solution was acidified with HCl (pH 1), filtered and the precipitate was washed with H₂O giving the sub-title compound in a 93% yield.

15 (b) *N*¹-isopropyl-5-cyano-2(2-oxiranylmethoxy)benzamide

The sub-title compound was prepared according to the method described in Example A above from *N*¹-*iso*-propyl-5-cyano-2-hydroxybenzamide (from step (a) above).

20 (c) *tert*-Butyl 7-{3-[*(4*-cyano-2-(*iso*-propylcarbamoyl)phenoxy]-2-hydroxypropyl}-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

The title compound was prepared according to the method described in Example 2 above from *N*¹-isopropyl-5-cyano-2(2-oxiranylmethoxy)-benzamide (from step (b) above).

25

¹³C NMR (CDCl₃): δ 22.64, 28.65, 28.76, 29.30, 31.73, 41.86, 47.64, 49.37, 60.35, 61.24, 64.93, 71.81, 79.49, 104.94, 113.45, 118.40, 123.71, 135.91, 136.47, 155.15, 159.64, 162.12

Example 12

tert-Butyl 7-[2-hydroxy-3-(4-nitrophenoxy)propyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

- 5 (a) 2[(4-Nitrophenoxy)methyl]oxirane

The sub-title compound was prepared according to the method described in Example A above from 4-nitrophenol.

- 10 (b) tert-Butyl 7-[2-hydroxy-3-(4-nitrophenoxy)propyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

The sub-title compound was prepared according to the method described in Example 2 above from 2[(4-nitrophenoxy)methyl]oxirane (from step (a) above).

- 15 ^{13}C NMR (CDCl_3): δ 28.64, 28.75, 29.35, 31.98, 47.54, 49.42, 56.83, 60.15, 61.55, 65.00, 71.10, 79.43, 93.82, 114.57, 125.73, 141.43, 155.94, 163.92

Example 13

- 20 tert-Butyl 7-[3-(4-aminophenoxy)-2-hydroxypropyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

The title compound was prepared quantitatively from *tert*-butyl 7-[2-hydroxy-3-(4-nitrophenoxy)propyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (see Example 12 above) using catalytic hydrogenation on 5% Pd/C in EtOH at 1 atm.

^{13}C NMR (CDCl_3): δ 28.64, 28.82, 29.36, 30.97, 31.78, 47.61, 49.28, 58.19, 60.30, 62.07, 65.28, 71.15, 79.41, 115.71, 116.29, 140.02, 152.04, 155.15

Example 14*tert*-Butyl 7-{2-hydroxy-3-[4-(methylsulfonamido)phenoxy]propyl}-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

5 MsCl (0.50 g; 4.40 mmol) was added to a stirred solution of *tert*-butyl 7-[3-(4-aminophenoxy)-2-hydroxypropyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (1.68 g; 4.29 mmol; see Example 13 above) in pyridine (20 mL). The reaction mixture was stirred for 2.5 h and subsequently concentrated. The residue was partitioned between DCM and NaHCO₃ (sat.), the organic layer separated, dried and concentrated. Purification using column chromatography (gradient 0 to 10% MeOH in DCM) gave the title compound in a 87% yield.

10

15 ¹³C NMR (CDCl₃): δ 28.70, 28.70, 28.84, 29.09, 29.42, 31.93, 38.77, 47.64, 49.42, 57.01, 60.29, 61.84, 65.20, 70.79, 79.50, 115.48, 116.32, 124.53, 129.40, 155.94, 157.28

Example 15*tert*-Butyl 7-[3-(4-cyano-2-methylphenoxy)-2-hydroxypropyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate(a) 2-Methyl-4-cyanophenol

The sub-title compound was prepared according to the method described in Example 10(b) above from 2-methyl-4-bromophenol.

25

(b) 3-Methyl-4-(2-oxiranylmethoxy)benzonitrile

The sub-title compound was prepared according to the method described in Example A above from 2-methyl-4-cyanophenol (from step (a) above).

52

(c) tert-Butyl 7-[3-(4-cyano-2-methylphenoxy)-2-hydroxypropyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

The title compound was prepared according to the method described in Example 2 above from 3-methyl-4-(2-oxiranylmethoxy)benzonitrile (from 5 step (b) above).

¹³C NMR (CDCl₃): δ 22.84, 28.52, 28.70, 28.89, 32.06, 47.61, 49.51, 56.96, 60.28, 62.00, 65.14, 68.32, 70.65, 79.5, 103.53, 111.26, 119.44, 128.25, 131.85, 133.87, 156.01, 160.40

10

Example 16

(tert-Butyl 7-[3-(2-amino-4-cyanophenoxy)-2-hydroxypropyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

15 (a) 3-Nitro-4-(2-oxiranylmethoxy)benzonitrile

4-Cyano-2-nitrophenol (0.80 g; 4.9 mmol) and K₂CO₃ (0.68 g; 4.9 mmol) were refluxed in MeCN (40 mL) for 1 h. The solvent was removed on a rotary evaporator and the residue dissolved in DMF (10 mL). 2-{[(3-Nitrophenyl)sulfonyloxy]methyl}oxirane (1.2 g, 4.9 mmol; see Example B 20 above) was added to the resultant solution. The solution was stirred at 40°C for 12 h and filtered. The precipitate was washed with H₂O to give the sub-title compound in a 65% yield.

(b) tert-Butyl 7-[3-(4-cyano-2-nitrophenoxy)-2-hydroxypropyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

3-Nitro-4-(2-oxiranylmethoxy)benzonitrile (2.9 g; 13.2 mmol; from step (a) above) was added to a stirred solution of *tert*-butyl 3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (3 g; 13.2 mmol; see Example F above) in IPA:H₂O (12.5 mL; 9:1), and the reaction mixture was refluxed

53

for 3 h. Concentration of the reaction mixture and purification by column chromatography (DCM:MeOH; 15:1) gave the title compound in a 54% yield.

5 ^{13}C NMR (CDCl_3): δ 28.4, 31.8, 47.4, 49.8, 56.7, 59.8, 60.5, 65.0, 71.9, 79.2, 103.7, 116.1, 116.7, 129.3, 137.3, 139.3, 155.4, 155.8

(c) (tert-Butyl 7-[3-(2-amino-4-cyanophenoxy)-2-hydroxypropyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

10 The title compound was prepared in a 98% yield according to the method described in Example 13 above from *tert*-butyl 7-[3-(4-cyano-2-nitrophenoxy)-2-hydroxypropyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (from step (b) above).

15 ^{13}C NMR (CDCl_3): δ 28.2, 31.7, 47.3, 49.2, 56.7, 59.9, 61.3, 65.4, 71.0, 79.2, 103.8, 111.5, 116.5, 119.6, 122.6, 137.4, 149.3, 155.7

Example 17

tert-Butyl 7-{3-[(4-cyano-2-(methylsulfonamido)phenoxy)-2-hydroxy-propyl}-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

The title compound was prepared in a 80% yield according to the method described in Example 14 above from *tert*-butyl 7-[3-(2-amino-4-cyanophenoxy)-2-hydroxypropyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (see Example 16 above).

25

^{13}C NMR (CDCl_3): δ 28.2, 28.5, 30.6, 39.4, 57.1, 59.4, 59.6, 64.9, 71.2, 77.4, 79.8, 104.3, 112.2, 118.4, 124.6, 129.5, 152.6, 155.7

Example 18tert-Butyl 7-[3-(4-cyano-2-[(ethylamino)carbonyl]amino]phenoxy]-2-hydroxypropyl}-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate5 (a) N-(5-Cyano-2-hydroxyphenyl)-N'-ethylurea

Ethyl isocyanate (7.1 g; 100 mmol) was added to a stirred solution of 2-amino-4-cyanophenol (13.4 g; 100 mmol) in MeCN (250 mL), and the resultant solution was stirred for 12 h. The precipitate was filtered off and dried (vacuum) to give the sub-title compound in a 70% yield.

10

(b) N-[5-Cyano-2-(oxiranylmethoxy)phenyl]-N'-ethylurea

The sub-title compound was prepared in a 52% yield according to the method described in Example 16(a) above from N-(5-cyano-2-hydroxyphenyl)-N'-ethylurea (from step (a) above).

15

(c) tert-Butyl 7-[3-(4-cyano-2-[(ethylamino)carbonyl]amino]phenoxy]-2-hydroxypropyl}-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

The title compound was prepared in a 40% yield according to the method described in Example 16(b) above from N-[5-cyano-2-(oxiranylmethoxy)phenyl]-N'-ethylurea (from step (b) above).

¹³C NMR (CDCl₃): δ 15.28, 28.63, 31.66, 34.73, 47.60, 49.42, 57.23, 59.70, 60.24, 65.79, 72.54, 79.71, 105.00, 113.17, 119.58, 121.22, 125.75, 131.44, 149.84, 155.50

25

Example 19*tert*-Butyl 7-[3-(3,4-dicyanophenoxy)-2-hydroxypropyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

- 5 (a) 4-(2-Oxiranylmethoxy)phthalonitrile

A stirred suspension of 4-hydroxyphthalonitrile (3.5 g; 24.3 mmol), K₂CO₃ (4.03 g; 29.2 mmol) and 2-{[(3-nitrophenyl)sulfonyloxy]methyl}-oxirane (6.50 g; 25.0 mmol; see Example B above) in MeCN (170 mL) was refluxed for 1.5 h. The cooled reaction mixture was filtered, the 10 filtrate concentrated and the solid residue recrystallized from IPA to give the sub-title compound.

- (b) *tert*-Butyl 7-[3-(3,4-dicyanophenoxy)-2-hydroxypropyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

15 The title compound was prepared in a 55% yield according to the method described in Example 2 above (using MeCN as solvent) from 4-(2-oxiranylmethoxy)phthalonitrile (from step (a) above).

¹³C NMR (CDCl₃): δ 28.8, 29.35, 31.96, 47.55, 49.45, 56.75, 60.12, 20 61.19, 65.14, 71.5, 79.47, 107.14, 115.19, 115.65, 117.15, 119.60, 120.06, 135.04, 155.98, 162.18

Example 20*tert*-Butyl 7-[2-(phenylcarbamoyl)ethyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

- 25 (a) N¹-Phenylacrylamide

Acryloyl chloride (28.5 mL; 350 mmol) was added to a stirred solution of phenylamine (30 mL; 320 mmol) and TEA (56 mL; 400 mmol) in THF (1

56

L) at 0°C. The reaction mixture was stirred for 3 h, poured onto brine and extracted with diethyl ether. The organic layer was dried, concentrated and recrystallized from hexane:EtOAc (3:1) to give the sub-title compound in a 79% yield.

5

- (b) *N*¹-Phenyl-3-(7-benzyl-3,7-diazabicyclo[3.3.1]non-3-yl)propanamide
- N*¹-Phenylacrylamide (1.0 g; 6.8 mmol; from step (a) above) was added to a stirred solution of 3-benzyl-3,7-diazabicyclo[3.3.1]nonane (1.5 g; 6.8 mmol; see Example E above) in EtOH (7 mL). The reaction mixture was stirred for 10 h and concentrated to give the sub-title compound in a 97% yield.
- (c) *tert*-Butyl 7-[2-(phenylcarbamoyl)ethyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate
- A solution of *N*¹-phenyl-3-(7-benzyl-3,7-diazabicyclo[3.3.1]non-3-yl)-propanamide (2.5 g; 6.8 mmol; from step (b) above) and di-*tert*-butyl dicarbonate (3.3 g; 15 mmol) in EtOH (25 mL) was hydrogenated over 5% Pd/C at 1 atm for 20 min., filtered through a pad of celite and concentrated. Purification by column chromatography (DCM:MeOH; 19:1) gave the title compound in a 90% yield.

¹³C NMR (CDCl₃): δ 28.55, 30.29, 35.84, 48.00, 49.14, 55.08, 58.09, 79.29, 120.15, 123.79, 128.87, 138.47, 156.07, 171.41

25

Example 21*tert*-Butyl 7-[3-(4-cyanophenoxypropyl)]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate5 (a) 4-(3-Bromopropoxy)benzonitrile

1,3-Dibromopropane (1.02 L; 10 mol) was added to a stirred suspension of *p*-cyanophenol (238 g; 2 mol), K₂CO₃ (276.4 g; 2 mol) in MeCN (2.7 L). The reaction mixture was refluxed for 4 h, filtered and concentrated. The residue was recrystallized from *iso*-propyl ether to give the sub-title compound in a 69% yield.

10

(b) *tert*-Butyl 7-[3-(4-cyanophenoxypropyl)]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

A stirred solution of 4-(3-bromopropoxy)benzonitrile (1.2 g; 52 mmol; from step (a) above), TEA (0.35 mL) and *tert*-butyl 3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (1.17 g; 52 mmol; see Example F above) in DMSO (2 mL) was heated to 60°C for 12 h. The reaction mixture was partitioned between Na₂CO₃ (aq.) and DCM and the organic layer separated, dried and subjected to column chromatography (DCM:MeOH; 22:1) to give the title compound in a 74% yield.

20

FAB-MS (M + 1)⁺ 386 (m/z)25 ¹³C NMR (CDCl₃): δ 26.47, 28.52, 28.87, 31.31, 47.54, 48.72, 55.21,

58.29, 59.26, 66.56, 78.46, 103.42, 115.19, 119.21, 133.78, 154.98,

162.28

Example 22tert-Butyl 7-{2-[(4-cyanophenyl)carbamoyl]ethyl}-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate5 (a) *N*¹-(4-Cyanophenyl)-3-chloropropanamide

3-Chloropropionylchloride (1.08 g; 8.5 mmol) was added to a cooled (10°C) solution of 4-cyanoaniline (1.0 g; 8.5 mmol) and pyridine (0.69 mL; 8.5 mmol) in DCM (40 mL), and the reaction mixture was stirred at rt. for 1 h. The reaction mixture was extracted with HCl (2N), washed with water, dried and concentrated to give the sub-title compound in a 81 % yield.

10 (b) tert-Butyl 7-{2-[(4-cyanophenyl)carbamoyl]ethyl}-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

15 The title compound was prepared in a 74% yield according to the method described in Example 21(b) above from *N*¹-(4-cyanophenyl)-3-chloropropanamide (from step (a) above).

20 ¹³C NMR (CDCl₃): δ 28.5, 30.5, 36.5, 48.1, 49.3, 55.1, 59.0, 79.5, 106.4, 119.1, 120.0, 133.1, 142.7, 156.3, 172.1

Example 23tert-Butyl 7-[3-(4-cyanoanilino)propyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

25 LiBH₄ (300 mg; 13.6 mmol) was added to a stirred solution of *tert*-butyl 7-{2-[(4-cyanophenyl)carbamoyl]ethyl}-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (1.36 g; 3.41 mmol; see Example 22 above) in toluene (10 mL) and THF (5 mL) and the reaction mixture was stirred for 45 min. The solvents were removed and the residue partitioned between DCM and

59

NaHCO₃ (aq.). The organic layer was concentrated and subjected to column chromatography (DCM:MeOH; 9:1) to give the title compound in a 10% yield.

5 ¹³C NMR (CDCl₃): δ 25.5, 28.6, 31.2, 41.1, 47.7, 48.8, 56.9, 59.0, 79.0, 97.4, 111.8, 120.7, 133.6, 151.7, 155.3

Example 24

10 *iso*-Propyl 7-[2-(4-cyanophenyl)-2-hydroxyethyl]-3,7-diazabicyclo[3.3.1]-nonane-3-carboxylate

(a) 4-(2-Oxiranyl)benzonitrile

15 NaBH₄ (1.6 g; 40 mmol) was added to a stirred solution of 4-cyanophenacyl bromide (8.8 g; 40 mmol) in THF (100 mL), and the reaction mixture was stirred until tlc indicated that the reaction was complete. The solvent was evaporated and the residue partitioned between DCM and H₂O, and the organic layer was separated, dried and concentrated. The residue was treated with K₂CO₃ (0.08 mol) in MeCN (85 mL) at room temperature overnight. The solvent was removed on a 20 rotary evaporator and the residue partitioned between CH₂Cl₂ and H₂O. The organic layer was washed with H₂O (2 x 100 mL), separated and dried to give the sub-title compound in 90% overall yield.

25 (b) *iso*-Propyl 7-[2-(4-cyanophenyl)-2-hydroxyethyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

The crude reaction mixture from step (a) above was condensed with *iso*-propyl 3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (5.2 g; see Example H above) according to the method described in Example 7 above to give the title compound in a 73% overall yield.

FAB-MS ($M + 1$)⁺ 358 (m/z)

¹³C NMR (CDCl₃): δ 22.39, 29.18, 32.76, 48.50, 49.38, 56.17, 59.90, 68.06, 68.46, 110.84, 119.03, 126.58, 132.04, 148.37, 157.32

5

Example 25

iso-Propyl 7-(4-cyanophenethyl)-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

10 (a) 4-Cyanophenethyl methanesulfonate

MsCl (18.6 g; 164 mmol) was added to a stirred solution of 4-(2-hydroxyethyl)benzonitrile (20 g; 136 mmol) and TEA (20.6 g; 204 mmol) in DCM (200 mL) at 0°C. The reaction mixture was stirred at rt. until tlc indicated that the reaction was complete. Water (200 mL) was added and 15 the organic layer was separated, dried and concentrated to give the subtitle compound in a quantitative yield.

(b) iso-Propyl 7-(4-cyanophenethyl)-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

20 iso-Propyl 3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (1.06 g; 5 mmol; see Example H above) was added to a stirred suspension of 4-cyanophenethyl methanesulfonate (1.13 g; 5 mmol; from step (a) above) and K₂CO₃ (0.96 g; 7 mmol) in MeCN (5 mL) under an inert atmosphere (N₂), and the reaction mixture was stirred for 10 h. The solvent was 25 evaporated and the residue partitioned between DCM and NaHCO₃ (aq.). The organic layer was separated, dried and concentrated. Purification using column chromatography (DCM:MeOH; 19:1) gave the title compound in a 88% yield.

61
FAB-MS ($M + 1$)⁺ 342 (m/z)

¹³C NMR (CD₃CN): δ 22.61, 22.67, 30.12, 30.16, 32.20, 34.02, 49.02, 49.18, 58.99, 59.68, 60.98, 68.26, 110.21, 119.89, 130.57, 132.99, 148.19, 156.33

5

Example 26

tert-Butyl 7-(2-{(benzyloxy)carbonyl}amino)ethyl)-3,7-diazabicyclo-[3.3.1]nonane-3-carboxylate

10 (a) Benzyl-N-(2-bromoethyl)carbamate

A solution of CBz-Cl (7.7 mL; 54 mmol) in dioxane (5 mL) was added to a cold (0°C) stirred solution of 2-bromoethylamine hydrobromide (10.0 g; 49 mmol) in 40 mL 1M NaOH:dioxane (3:1) under Schotten-Bauman conditions. The reaction mixture was allowed to attain rt. and extracted 15 with CHCl₃. The organic layer was separated, concentrated and purified by column chromatography (CHCl₃) to give the sub-title compound in a 92% yield.

20 (b) tert-Butyl 7-(2-{(benzyloxy)carbonyl}amino)ethyl)-3,7-diazabicyclo-[3.3.1]nonane-3-carboxylate

The title compound was prepared in a 44% yield according to the method in Example 25(b), using benzyl-N-(2-bromoethyl)carbamate (from step (a) above).

25 ¹³C NMR (CDCl₃): δ 28.64, 31.96, 37.89, 47.67, 49.38, 57.72, 59.30, 66.30, 79.11, 127.71, 128.05, 128.30, 137.08, 155.77, 156.88

Example 27*tert*-Butyl 7-{2-[4-cyanobenzylamino]ethyl}-3,7-diazabicyclo[3.3.1]-nonane-3-carboxylate

- 5 (a) *tert*-Butyl 7-[2-aminoethyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

The sub-title compound was prepared according to the method described in Example E(b) in a quantitative yield from *tert*-butyl 7-{[(benzyloxy)-carbonyl]amino}ethyl)-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (see 10 Example 26 above).

- (b) *tert*-Butyl 7-{2-[4-cyanobenzylamino]ethyl}-3,7-diazabicyclo[3.3.1]-nonane-3-carboxylate

p-Cyanobenzylbromide (0.765 g; 3.9 mmol) was added to a stirred 15 solution of *tert*-butyl 7-[2-aminoethyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (1.04 g; 3.9 mmol; from step (a) above) in MeCN (15 mL) and the reaction mixture was stirred at 40°C for 32 h. The solvent was evaporated and the residue subjected to column chromatography (EtOAc) to give the title compound in a 74% yield.

20

¹³C NMR (CD₃OD): δ 27.65, 29.17, 31.06, 51.92, 57.34, 58.41, 78.86, 110.41, 118.41, 129.23, 131.89, 145.74, 155.91

25

Example 28

(R,R)- and (R,S) or (S,R)- and (S,S)-*tert*-Butyl 7-[4-(4-cyanophenyl)-2,4-dihydroxybutyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

5 (a) 4-Acetoxy-4-(*p*-cyanophenyl)-1-butene

The sub-title compound was prepared according to the method described in J. Am. Chem. Soc., 110, 3601 (1988).

10 (b) 1-(4-Cyanophenyl)-2-(2-oxiranyl)ethyl acetate

10 *m*CPBA (2.86 g; 70%) was added to a stirred solution of 4-acetoxy-4-(*p*-cyanophenyl)-1-butene (2.5 g; 11.6 mmol; from step (a) above) in DCM (20 mL), and the reaction mixture was refluxed for 3 h and then cooled. The *m*-chlorobenzoic acid was removed by filtration and the filtrate was washed with NaHCO₃ (aq.), then with water, the phases were separated, 15 dried, concentrated and purified by column chromatography (DCM) to give the sub-title compound in a 50% yield.

15 (c) *tert*-Butyl 7-[4-(4-cyanophenyl)-2-hydroxy-4-(methylcarbonyloxy)-butyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

20 The sub-title compound was prepared in a 82% yield according to the method described in Example 2 above using 1-(4-cyanophenyl)-2-(2-oxiranyl)ethyl acetate (from step (b) above).

FAB-MS (M + 1)⁺ 458 (m/z)

25 ¹³C NMR (CDCl₃): δ 21.04, 28.57, 29.34, 31.81, 41.88, 47.58, 56.97, 60.51, 62.43, 65.46, 72.47, 79.41, 111.36, 118.59, 126.82, 132.22, 145.85, 155.99, 169.83

64

(d) (R,R)- and (R,S) or (S,R)- and (S,S)-*tert*-Butyl 7-[4-(4-cyanophenyl)-2,4-dihydroxybutyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

tert-Butyl 7-[4-(4-cyanophenyl)-2-hydroxy-4-(methylcarbonyloxy)butyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (1.88 g; 4.12 mmol; from 5 step (c) above) was deprotected as follows: A solution of NaOH (0.21 g; 5 mmol) in MeOH (2 mL) was added to a stirred solution of the protected intermediate in MeOH (2 mL). The reaction mixture was refluxed for 2 h, partitioned between diethyl ether and water, and the organic layer separated, dried, concentrated and subjected to column chromatography (DCM:MeOH; 49:1) to give two separable diastereomeric pairs in a 88% 10 yield. The title compound was isolated as the less polar diastereoisomers.

ESI-MS ($M + 1$)⁺ 417 (m/z)

¹³C NMR (CDCl₃): δ 28.25, 28.88, 30.69, 31.54, 43.18, 47.19, 48.31, 15 49.02, 56.29, 59.68, 64.65, 66.34, 72.97, 79.13, 110.09, 118.55, 126.10, 131.57, 149.93, 155.59

Example 29

(S,R)- and (S,S)- or (R,R)- and (R,S)-*tert*-Butyl 7-[4-(4-cyanophenyl)-2,4-dihydroxybutyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

The title compound was isolated as the more polar diastereoisomers from Example 28 above.

ESI-MS ($M + 1$)⁺ 416 (m/z)

25 ¹³C NMR (CDCl₃): δ 28.35, 29.00, 30.78, 31.62, 42.07, 47.24, 48.32, 49.13, 56.34, 59.86, 63.16, 64.27, 70.15, 79.23, 110.00, 118.73, 126.15, 131.68, 150.59, 155.68

Example 30*tert*-Butyl 7-[4-(4-cyanophenyl)-4-hydroxybutyl]-3,7-diazabicyclo[3.3.1]-nonane-3-carboxylate5 (a) 4-1(-{[1-(*tert*-Butyl)-1,1-dimethylsilyl]oxy}-3-but enyl)benzonitrile

Imidazole (11.5 g; 170 mmol) was added to a stirred solution of 1-(*p*-cyanophenyl)-3-buten-1-ol (11.5 g; 87 mmol) and *tert*-butyldimethylsilyl chloride (12 g; 80 mmol) in DMF (50 mL), and the reaction mixture was stirred under N₂(g) for 10 h. The solvent was evaporated and the residue partitioned between water and diethyl ether. The organic layer was separated, dried, concentrated and subjected to column chromatography (DCM) to give the sub-title compound in a 86% yield.

10 (b) 4-1(-{[1-(*tert*-Butyl)-1,1-dimethylsilyl]oxy}-4-hydroxybutyl)benzonitrile

Borane-methyl sulfide complex (13 mL; 2M; 26 mmol) was added to a stirred and cooled (0°C) solution of 4-1(-{[1-(*tert*-butyl)-1,1-dimethylsilyl]oxy}-3-but enyl)benzonitrile (15.2 g; 53 mmol; from step (a) above) in THF (100 mL). The temperature was raised to rt. and stirred until tlc indicated complete consumption of the starting material. The temperature was lowered to 0°C and a solution of sodium perborate tetrahydrate (19 g; 123 mmol) in water (55 mL) was added and the resultant reaction mixture was stirred at rt. for 12 h. Brine (100 mL) and diethyl ether (150 mL) was added and the organic layer was separated, dried, concentrated and subjected to column chromatography (hexane:EtOAc; 1:1) to give the sub-title compound in a 85% yield.

(c) 4-{-[1-(*tert*-Butyl)-1,1-dimethylsilyl]oxy}-4-(4-cyanophenyl)butyl methanesulfonate

The sub-title compound was prepared in a 98% yield according to the method described in Example 25(a) above from 4-1(-{[1-(*tert*-butyl)-1,1-dimethylsilyl]oxy}-4-hydroxybutyl)benzonitrile (from step (b) above).

(d) *tert*-Butyl 7-[4-(4-cyanophenyl)-4-{[-1-(*tert*-butyl)-1,1-dimethylsilyl]oxy}butyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

The sub-title compound was prepared in 96% yield according to the method described in Example 25(b) above from 4-{[-1-(*tert*-butyl)-1,1-dimethylsilyl]oxy}-4-(4-cyanophenyl)butyl methanesulfonate (from step (c) above) and *tert*-butyl 3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (see Example F above).

(e) *tert*-Butyl 7-[4-(4-cyanophenyl)-4-hydroxybutyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

Tetrabutylammonium fluoride (0.95 mmol) was added to a stirred solution of *tert*-butyl 7-[4-(4-cyanophenyl)-4-{[-1-(*tert*-butyl)-1,1-dimethylsilyl]oxy}butyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (0.44 g; 0.85 mmol; from step (d) above) in THF (5 mL), and the resultant reaction mixture was stirred for 2 h. The solvent was evaporated and the residue was subjected to column chromatography (MeCN:MeOH; gradient 0 to 10% MeOH) to give the title compound in a 70% yield.

ESI-MS ($M + 1$)⁺ 400 (m/z)

¹³C NMR (CDCl₃): δ 22.26, 28.37, 30.10, 37.26, 37.63, 47.68, 48.53, 57.73, 58.34, 59.12, 72.49, 78.95, 110.03, 119.05, 126.59, 131.71, 151.05, 155.58

Example 31iso-Propyl 7-[4-(4-cyanophenyl)-4-hydroxybutyl]-3,7-diazabicyclo[3.3.1]-nonane-3-carboxylate

5 (a) 3-(4-Cyanophenyl)-4-hydroxybutyl]-3,7-diazabicyclo[3.3.1]nonane
HCl-saturated EtOAc (200 mL) was added to a stirred solution of *tert*-butyl 7-[4-(4-cyanophenyl)-4-{[-1-(*tert*-butyl)-1,1-dimethylsilyl]oxy}-butyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (4.60 g; see Example 30(d) above) in EtOAc (50 mL), and the reaction mixture was stirred for 2
10 h. The solvent was evaporated and the residue dissolved in EtOH and passed through an ion-exchange resin (Amberlyst IRA 400), concentrated and lyophilized to give the sub-title compound in a quantitative yield.

15 (b) iso-Propyl 7-[4-(4-cyanophenyl)-4-hydroxybutyl]-3,7-diazabicyclo-[3.3.1]nonane-3-carboxylate

The title compound was prepared in a 77% yield according to the method described in Example H(a) above from 3-(4-cyanophenyl)-4-hydroxybutyl]-3,7-diazabicyclo[3.3.1]nonane (from step (a) above).

20 FAB-MS ($M + 1$)⁺ 386 (m/z)

¹³C NMR (CDCl₃): δ 22.33, 23.02, 28.57, 28.71, 30.78, 37.35, 48.21, 57.91, 58.50, 58.89, 59.46, 68.13, 72.54, 73.07, 110.17, 119.21, 126.61, 131.84, 151.26, 156.03

Example 32

iso-Propyl 7-[(2S)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

- 5 (a) [(2S)-2-Methyloxiran-2-yl)methyl 3-nitro-1-benzenesulfonate

The sub-title compound was prepared according to the method described in Example B above from *R*-(+)-2-methylglycidol.

- (b) 4-{[(2S)-Methyloxiran-2-yl)methoxy}benzonitrile

10 A suspension of [(2S)-2-methyloxiran-2-yl)methyl 3-nitro-1-benzenesulfonate (37.7 g; 138 mmol; from step (a) above), K_2CO_3 (28 g) and *p*-cyanophenol (23.8 g; 200 mmol) in MeCN (300 mL) was refluxed for 20 h. The reaction mixture was filtered and the filtrate concentrated under reduced pressure, dissolved in ether and washed with 2M NaOH and then brine. The organic layer was concentrated and subjected to column chromatography (petroleum ether:EtOAc; 3:1) to give the sub-title compound.

- 15 (c) iso-Propyl 7-[(2S)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

The title compound was prepared according to the method described in Example 7 above from 4-{[(2S)-methylloxiran-2-yl)methoxy}benzonitrile (from step (b) above).

20 ^{13}C NMR ($CDCl_3$): δ 22.38, 22.80, 29.20, 29.56, 31.11, 48.09, 60.93, 61.78, 64.19, 68.83, 71.32, 72.24, 103.91, 115.42, 119.25, 134.01, 155.26, 161.94

Example 33tert-Butyl 7-[(2S)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

The title compound was prepared according to the method described in
5 Example 2 above from 4-{[(2S)-methyloxiran-2-yl]methoxy}benzonitrile
(see Example 32(b) above).

ESI-MS ($M + 1$)⁺ 416 (m/z)

10 ^{13}C NMR (CDCl_3): δ 22.55, 28.57, 29.51, 30.92, 47.93, 48.62, 60.82,
62.04, 63.84, 71.41, 80.0, 104.01, 119.23, 134.09, 154.74, 161.92

Example 342-Hydroxy-1,1-dimethylethyl 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

15

(a) Ethyl-2-(chlorocarbonyloxy)-2-methylpropanoate

The sub-title compound was prepared according to the method described
in Zh. Org. Khim., 7, 1875 (1971).

20 (b) 2-Ethoxy-1,1-dimethyl-2-oxyethyl 7-benzyl-3,7-diazabicyclo[3.3.1]-nonane-3-carboxylate

A solution of 3-benzyl-3,7-diazabicyclo[3.3.1]nonane (23.8 g; 110 mmol;
see Example E above) in toluene (100 mL) was added to a stirred solution
of ethyl-2-(chlorocarbonyloxy)-2-methylpropanoate (100 mmol) in toluene
25 (25 mL). The reaction mixture was cooled to 0°C and TEA (25 mL; 180
mmol) was added. After 2 h, the salts were filtered off and the residue
concentrated, dissolved in DCM and washed with NaHCO_3 (aq.). The
organic layer was separated, dried and concentrated to give the sub-title
compound in a 90% yield.

(c) 2-Hydroxy-1,1-dimethylethyl 7-benzyl-3,7-diazabicyclo[3.3.1]-nonane-3-carboxylate

LiBH₄ (0.6 g; 26.7 mmol) was added to a stirred solution of 2-ethoxy-1,1-dimethyl-2-oxymethyl 7-benzyl-3,7-diazabicyclo[3.3.1]-nonane-3-carboxylate (5 g; 13.35 mmol; from step (b) above) in THF (30 mL) and toluene (20 mL), and the reaction mixture was heated at 100°C for 30 min. Water (10 mL) and NaHCO₃ (aq.) was added and the solution was extracted with DCM. The organic layer was washed with water (3 x 100 mL), separated, dried, concentrated and subjected to column chromatography (DCM:MeOH sat. with NH₃; 35:1) to give the sub-title compound in a 20% yield.

(d) 2-Hydroxy-1,1-dimethylethyl 7-[3-(4-cyanophenoxy)-2-hydroxy-propyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

2-Hydroxy-1,1-dimethylethyl 7-benzyl-3,7-diazabicyclo[3.3.1]-nonane-3-carboxylate (from step (c) above) was debenzylated according to the method described in Example E(b) above and subsequently reacted with 4-(2-oxiranylmethoxy)benzonitrile (see Example A above) in accordance with the method described in Example 2 above to give the title compound in an overall yield of 88%.

ESI-MS (M + 1)⁺ 418 (m/z)

¹³C NMR (CDCl₃): δ 26.02, 26.66, 29.25, 29.47, 32.73, 48.91, 49.65, 56.52, 60.07, 62.27, 65.08, 69.85, 70.63, 72.86, 104.08, 115.33, 119.17, 133.90, 157.68, 162.12

Example 351-Cyano-1-methylethyl 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate5 (a) 1-Cyano-1-methylethyl chloroformate

A solution of acetone cyanohydrin (5 g; 59 mmol) in pyridine (5 mL) was added to a stirred solution of COCl₂ (30 mL; 1.92 M; 59 mmol) at -15°C. The temperature was raised to rt. and the reaction mixture was stirred for 2 h. The precipitate was filtered off and the filtrate was concentrated and 10 used directly in the next step without further purification.

(b) 1-Cyano-1-methylethyl 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]- 3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

1-Cyano-1-methylethyl chloroformate (0.4 g; 1.65 mmol; from step (a) 15 above) was added to a stirred solution of 4-[3-(3,7-diazabicyclo[3.3.1]non-3-yl)-2-hydroxypropoxy]benzonitrile (0.5 g; 1.65 mmol; see Example G above) and K₂CO₃ (0.7 g) in MeCN (25 mL). The reaction mixture was stirred at 40°C for 2 h. The salts were filtered off and the filtrate was concentrated and subjected to column chromatography (DCM:MeOH; 20 19:1) to give the title compound in a 59% yield.

ESI-MS (M + 1)⁺ 413 (m/z)

¹³C NMR (CDCl₃): δ 27.29, 27.78, 28.60, 29.13, 31,31, 48.30, 49.22, 57.90, 60.29, 61.52, 65.66, 68.90, 70.67, 104.101, 115.46, 119.22, 25 120.29, 133.96, 153.58, 162.19

Example 363,4-Dimethoxyphenethyl 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

- 5 (a) 3,4-Dimethoxyphenethyl 7-benzyl- 3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

3,4-Dimethoxyphenethyl alcohol (3.64 g; 20 mmol) was added to a stirred suspension of 1,1'-carbonyldiimidazole (3.24 g; 20 mmol) in THF (20 mL), and the mixture was refluxed for 12 h. A solution of 3-benzyl-3,7-diazabicyclo[3.3.1]nonane (4.33 g; 20 mmol; see Example E above) in THF (20 mL) was added and the reaction mixture was refluxed overnight. The solvent was removed and the residue dissolved in H₂SO₄ (2M; 25 mL) and extracted with diethyl ether. NaOH (3.5 mL; 5M) was added and the aqueous phase extracted with DCM. The organic layer was separated, dried and subjected to column chromatography (DCM:MeOH; gradient 0 to 30% MeOH) to give the sub-title compound in a 29% yield.

- (b) 3,4-Dimethoxyphenethyl 3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

The sub-title compound was prepared in a 70% yield according to the method described in Example E(b) above from 3,4-dimethoxyphenethyl 7-benzyl-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (from step (a) above).

- (c) 3,4-Dimethoxyphenethyl 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

25 The title compound was prepared in a 45% yield according to the method described in Example 2 above from 3,4-dimethoxyphenethyl 3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (from step (b) above).

73

¹³C NMR (CDCl₃): δ 28.9, 32.3, 34.8, 48.3, 49.0, 55.5, 56.2, 59.5, 62.0, 64.6, 65.7, 70.6, 103.6, 111.0, 112.2, 115.0, 118.8, 120.7, 130.8, 133.5, 147.3, 148.5, 157.1, 161.8

5 Example 37

Phenyl 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-3,7-diazabicyclo[3.3.1]-nonane-3-carboxylate

Phenyl chloroformate (0.36 mL; 2.9 mmol) and NaOH (0.52 mL; 10M, 5.2 mmol) were added to a stirred solution of 4-[3-(3,7-diazabicyclo[3.3.1]non-3-yl)-2-hydroxy-propoxy]benzonitrile (0.796 g; 2.6 mmol; see Example G above) in toluene (5 mL). The reaction mixture was stirred at rt. for 15 min. DCM was added and the organic layer was separated, dried, concentrated and recrystallized from IPA to give the title compound in a 86% yield.

15

¹³C NMR (CDCl₃): δ 28.8, 29.2, 32.0, 48.6, 49.6, 56.9, 60.0, 62.1, 65.1, 70.5, 103.7, 115.2, 119.0, 121.6, 124.9, 128.9, 133.6, 151.1, 154.9, 162.0

20 Example 38

Benzyl 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-3,7-diazabicyclo[3.3.1]-nonane-3-carboxylate

The title compound was prepared in quantitative yield according to the method described in Example 1 above from CBz-OSu, using TEA, instead 25 of NaOH, as a base.

ESI-MS (M + 1)⁺ 436 (m/z)

74

¹³C NMR (CDCl₃): δ 29.31, 32.70, 48.88, 49.55, 56.77, 60.21, 62.47, 65.13, 67.28, 70.86, 104.04, 115.40, 119.23, 127.93, 128.43, 133.94, 136.91, 157.39, 166.22

5 Example 39

tert-Butyl 7-[(2S)-3-(4-cyanophenoxy)-2-hydroxypropyl]-9-(1,2-ethylenedioxy)-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

(a) 3,7-Dibenzyl 9-(1,2-ethylenedioxy)-3,7-diazabicyclo[3.3.1]nonane

10 A solution of 3,7-dibenzyl-3,7-diazabicyclo[3.3.1]nonane-9-one (10.0 g; 29.8 mmol; Bionet), ethylene glycol (20 g) and *p*-TSA (12.5 g; 65.7 mmol) in toluene (200 mL) was refluxed in a Dean-Stark apparatus for 12 h. NaOH (200 mL, 2M) was added and the organic layer separated, dried and concentrated to give the sub-title compound in a quantitative yield.

15

(b) tert-Butyl 7-benzyl-9-(1,2-ethylenedioxy)-3,7-diazabicyclo[3.3.1]-nonane-3-carboxylate

The sub-title compound was prepared in a 92% yield according to the method described in Example 20(c) above from 3,7-dibenzyl 9-(1,2-ethylenedioxy)-3,7-diazabicyclo[3.3.1]nonane (from step (a) above).

(c) tert-Butyl 9-(1,2-ethylenedioxy)-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

25 The sub-title compound was prepared in quantitative yield according to the method described in Example E(b) above from *tert*-butyl 7-benzyl-9-(1,2-ethylenedioxy)-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (from step (b) above).

75

(d) tert-Butyl 7-[(2S)-3-(4-cyanophenoxy)-2-hydroxypropyl]-9-(1,2-ethylenedioxy)-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

The title compound was prepared in a 44% yield according to the method described in Example 3 above from *tert*-butyl 9-(1,2-ethylenedioxy)-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (from step (c) above).

¹³C NMR (CDCl₃): δ 28.78, 37.71, 38.37, 46.00, 47.42, 53.83, 57.81, 60.81, 64.40, 65.45, 70.80, 79.81, 104.06, 106.95, 115.44, 119.24, 133.93, 156.24, 162.27

10

Example 40

tert-Butyl 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-9,9-pentamethylene-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

15 (a) N-(Cyanoacetyl) benzylamide

A mixture of benzyl amine (150 mL; 1.4 mol) and methyl cyanoacetate (130 mL; 1.4 mol) was stirred at 100°C for 16 h with continuous removal of MeOH. The reaction mixture was allowed to attain rt. and the precipitate filtered off and washed with cold EtOH to give the sub-title 20 compound in a 78% yield.

(b) Ethyl (2-cyclopentylidene)cyanoacetate

The sub-title compound was prepared in a 69% yield analogously to the method described in Organic Synthesis, 39, 25 (1959) from 25 cyclopentanone and ethyl cyanoacetate.

(c) 8-Benzyl-7,9-dioxo-8-azaspiro[4.5]decane-6,10-dicarbonitrile

N-(Cyanoacetyl) benzylamide (2.30 g; 13.2 mmol; from step (a) above) and ethyl (2-cyclopentylidene)cyanoacetate (2.36 g; 13.2 mmol; from step

(b) above) were added to a stirred solution of sodium ethoxide (13 mmol) in EtOH (20 mL), and the reaction mixture was stirred at rt. for 96 h. Water (16 mL) and HCl (5 mL, conc.) were added and the precipitate filtered off, washed with water and dried *in vacuo* to give the sub-title compound in a 55% yield.

5 (d) 3-Benzyl-9,9-pentamethylene-3,7-diazabicyclo[3.3.1]nonane-2,4,6,8-tetraone

10 8-Benzyl-7,9-dioxo-8-azaspiro[4.5]decane-6,10-dicarbonitrile (4.0 g; 13 mmol; from step (c) above) was stirred in H₂SO₄ (20 mL, conc.) and H₃PO₄ (85 %) for 40 min. at 120°C. The hot reaction mixture was poured on ice-water and the precipitate filtered off, washed with EtOH and dried *in vacuo* to give the sub-title compound in a 43% yield.

15 (e) 3-Benzyl-9,9-pentamethylene-3,7-diazabicyclo[3.3.1]nonane

3-Benzyl-3,7-diazabicyclo[3.3.1]nonane-2,4,6,8-tetraone (from step (d) above) was reduced with LiAlH₄ in dioxane using standard procedures to give the sub-title compound in a quantitative yield.

20 (f) tert-Butyl 7-benzyl-9,9-pentamethylene-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

Di-*tert*-butyl dicarbonate (0.92 g; 4.2 mmol) was added to a solution of 3-benzyl-9,9-pentamethylene-3,7-diazabicyclo[3.3.1]nonane (1.15 g; 4.2 mmol; from step (e) above) in THF (50 mL) and the reaction mixture was stirred until tlc indicated that the reaction was complete. The solvent was removed on a rotary evaporator to give the sub-title compound in a 79% yield.

77

^{13}C NMR (CDCl_3): δ 23.80, 28.64, 30.26, 34.87, 35.21, 37.40, 42.43, 46.09, 46.68, 55.92, 56.46, 62.80, 78.58, 126.53, 128.00, 128.32, 139.53, 155.37

5 (g) tert-Butyl 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-9,9-penta-
methylene-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

The title compound was prepared in a 53% overall yield according to the methods described in Examples E(b) and 2 above from *tert*-butyl 7-benzyl-9,9-pentamethylene-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (from
10 step (f) above).

^{13}C NMR (CDCl_3): δ 23.83, 28.68, 35.13, 37.30, 42.77, 45.82, 46.84, 47.02, 54.26, 57.90, 61.04, 65.34, 70.77, 79.32, 104.03, 115.44, 119.17, 133.85, 156.00, 162.34

15

Example 41

7-(*tert*-Butyloxycarbonyl)-3-[3-(4-cyanophenoxy)-2*S*-hydroxypropyl]-3-
methyl-7-aza-3-azoniabicyclo[3.3.1]nonane acetate

MeI (1.5 mmol) was added to a stirred solution of *tert*-butyl 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-3,7-diazabicyclo[3.3.1]nonane-3-
20 carboxylate (0.5 g; 1.24 mmol; see Example 2 above) in DMF (4 mL), and the reaction mixture was stirred at rt. for 48 h. Toluene was then added and the solvents removed under vacuum. The residue was purified using HPLC (MeCN:H₂O; 70:30 isocratic; NH₄OAc-buffer; C8 column).
25 The resultant salt was obtained by freeze-drying the appropriate fractions.

FAB-MS ($M + 1$)⁺ 416 (m/z)

^{13}C NMR (CD_3OD): δ 25.88, 27.24, 27.66, 57.76, 64.42, 66.18, 70.48, 81.93, 104.18, 115.40, 118.52, 133.84, 156.04, 162.12

Example 427-(*tert*-Butyloxycarbonyl)-3-[3-(4-cyanophenoxy)-2-hydroxypropyl]-7-aza-3-azoniabicyclo[3.3.1]nonan-3-olate

5 *m*CPBA (300 mg; 70%; 1.22 mmol) was added to a stirred solution of
tert-butyl 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-3,7-diazabicyclo-[3.3.1]nonane-3-carboxylate (490 mg; 1.22 mmol; see Example 2 above)
in DCM (10 mL) at 0°C. The reaction mixture was stirred for 1 h and
then washed with NaHCO₃ (aq.). The organic layer separated, dried,
10 concentrated and subjected to column chromatography (DCM:MeOH;
19:1) to give the title compound in a 98% yield.

FAB-MS (M + 1)⁺ 418 (m/z)

13C NMR (CDCl₃): δ 27.63, 28.52, 46.16, 65.30, 68.45, 70.53, 72.03,
15 72.53, 78.98, 104.23, 115.28, 119.04, 133.96, 155.51, 161.68

Example 437-(*tert*-Butyloxycarbonyl)-3-[(2S)-3-(4-cyanophenoxy)-2-hydroxypropyl]-7-aza-3-azoniabicyclo[3.3.1]nonan-3-olate

20 The title compound was prepared in a 70% yield according to the method
described in Example 42 above from 3,7-diazabicyclo[3.3.1]nonane-3-
carboxylic acid, 7-[(2S)-3-(4-cyanophenoxy)-2-hydroxypropyl]-1,1-
dimethylethyl ester (see Example 3 above).

25 FAB-MS (M + 1)⁺ 417 (m/z)

Example 447-(Cyclopentyloxycarbonyl)-3-[3-(4-cyanophenoxy)-2-hydroxypropyl]-7-aza-3-azoniabicyclo[3.3.1]nonane-3-olate

The title compound was prepared in a 86% yield according to the method described in Example 42 above from cyclopentyl 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (see Example 9 above).

FAB-MS ($M + 1$)⁺ 430 (m/z)

10 ^{13}C NMR (CDCl_3): δ 23.68, 27.41, 32.61, 45.80, 65.21, 68.29, 70.30, 72.17, 72.71; 77.60, 104.43, 115.10, 115.21, 118.95, 133.83, 134.11, 156.10, 161.45

Example 457-(*tert*-Butyloxycarbonyl)-3-[3-(4-cyanophenoxy)propyl]-7-aza-3-azoniabicyclo[3.3.1]nonan-3-olate

The title compound was prepared in a 80% yield according to the method described in Example 42 above from *tert*-butyl 7-(3-cyanophenoxypropyl)-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (see Example 21 above).

20

FAB-MS ($M + 1$)⁺ 402 (m/z)

^{13}C NMR (CDCl_3): δ 22.40, 27.12, 27.31, 28.50, 46.00, 66.04, 69.46, 70.58, 79.41, 104.23, 115.15, 119.05, 134.03, 155.54, 161.68

25 Example 46

7-(*tert*-Butyloxycarbonyl)-3-[3-(4-cyanoanilino)propyl]-7-aza-3-azoniabicyclo[3.3.1]nonan-3-olate

The title compound was prepared in a 6% yield according to the method described in Example 42 above from *tert*-butyl 7-[3-(4-

80
cyanoanilino)propyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (see Example 23 above).

FAB-MS ($M + 1$)⁺ 401 (m/z)

5 ¹³C NMR (CDCl₃): δ 18.5, 22.3, 25.4, 27.3, 27.4, 28.6, 72.8, 79.2, 97.3, 112.1, 121.0, 133.6, 152.0, 155.5

Example 47

10 n-Butyl 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-3,7-diazabicyclo[3.3.1]-nonane-3-carboxylate

15 4-[3-(3,7-Diazabicyclo[3.3.1]non-3-yl)-2-hydroxypropoxy]benzonitrile hydrochloride, (1 g; 2.96 mmol; see Example G above) was suspended in CH₂Cl₂ (20 mL) and saturated NaHCO₃ (40 mL). n-Butyl chloroformate was added (1.12 eq.; 3.33 mmol) and the reaction was stirred at room temperature overnight (18 to 20 h) under N₂. The crude material was chromatographed on a 3 cm x 18 cm silica gel column eluting with hexanes:ethyl acetate (2:1). All fractions containing the desired material were combined to give 420 mg (1.20 mmol; 41% yield) of the title compound.

20

¹H NMR (CDCl₃): δ 7.58 (d, 2H), 6.95 (d, 2H), 4.40-3.90 (m, 8H), 3.30-2.85 (m, 4H), 2.60-1.20 (m, 12 H), 0.95 (t, 3H)

13C NMR (CDCl₃): δ 162.0, 157.5, 133.0, 119.0, 115.5, 104.0, 71.0, 70.5, 66.0, 65.5, 65.0, 62.5, 62.0, 61.0, 60.0, 58.0, 56.5, 49.5, 48.5, 25 33.0, 32.0, 31.0, 29.5, 29.0, 19.0, 13.5.

CI-MS ($M + 1$)⁺ 402 (m/z)

Example 482-Chloroethyl 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

Prepared according to the method described in Example 47 above using 2-chloroethyl chloroformate, yielding 783 mg (2.03 mmol; 69% yield) of the title compound.

¹H NMR (CDCl₃): δ 7.55 (d, 2H), 6.95 (d, 2H), 4.50-4.10 (m, 6H), 4.10-3.90 (m, 3H), 3.90-3.60 (m, 2H), 3.30-3.00 (m, 5H), 2.65-2.29 (m, 10 3H), 2.20-2.05 (m, 2H), 1.95-1.65 (m, 5H)

¹³C NMR (CDCl₃): δ 162.0, 134.0, 119.0, 115.5, 71.0, 70.5, 66.2, 65.0, 62.5, 62.0, 61.0, 60.0, 58.0, 56.5, 49.5, 48.5, 48.4, 43.0, 42.5, 32.7, 32.0, 29.5, 29.0

CI-MS (M + 1)⁺ 408 (m/z)

15 mp 104-105°C

Example 49Allyl 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-3,7-diazabicyclo[3.3.1]-nonane-3-carboxylate

20 Prepared according to the method described in Example 47 above using allyl chloroformate, yielding 828 mg (2.15 mmol; 73% yield) of title compound.

¹H NMR (CDCl₃): δ 7.52-7.40 (d, 2H), 6.95-6.80 (d, 2H), 5.90-5.75 (m, 25 1H), 5.25-5.05 (m, 2H), 4.75-4.40 (m, 2H), 4.40-3.80 (m, 6H), 3.20-2.80 (m, 4H), 2.60-1.50 (m, 8H)

¹³C NMR (CDCl₃): δ 162.0, 134.0, 133.5, 119.0, 117.0, 115.0, 104.5, 71.0, 70.5, 66.0, 65.5, 62.5, 62.0, 60.0, 58.0, 57.0, 49.0, 48.0, 32.0, 31.5, 29.5

CI MS (M + 1)⁺ 386 (m/z)

Example 50

n-Propyl 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-3,7-diazabicyclo-[3.3.1]nonane-3-carboxylate

Prepared according to the method described in Example 47 above using *n*-propyl chloroformate, yielding 780 mg (2.01 mmol; 68% yield) of the title compound.

10 ¹H NMR (CDCl₃): δ 7.65-7.55 (d, 2H), 7.05-6.95 (d, 2H), 4.45-3.90 (m, 9H), 3.30-2.85 (m, 4H), 2.60-2.00 (m, 4H), 1.95-1.60 (m, 5H), 1.00-0.90 (t, 3H)

15 ¹³C NMR (CDCl₃): δ 162.0, 134.0, 119.0, 117.0, 104.0, 71.5, 67.5, 65.5, 63.0, 61.5, 57.5, 49.5, 49.0, 33.0, 32.0, 29.5, 22.0, 11.0
15 CI MS (M + 1)⁺ 388 (m/z)

Example 51

4-Nitrobenzyl 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-3,7-diazabicyclo-[3.3.1]nonane-3-carboxylate

20 Prepared according to the method described in Example 47 above using 4-nitrobenzyl chloroformate, yielding 958 mg (2.00 mmol; 68% yield) of the title compound as a yellow crystalline solid.

25 ¹H NMR (CDCl₃): δ 8.25-8.15 (d, 2H), 7.65-7.45 (m, 4H), 7.05-6.90 (d, 2H), 5.40-5.10 (m, 2H), 4.48-4.15 (m, 3H), 4.05-3.85 (m, 3H), 3.34-2.90 (m, 5H), 2.63-2.30 (m, 4H), 2.00-1.69 (m, 4H)

13C NMR (CDCl₃): δ 162.0, 144.5, 134.0, 128.0, 123.5, 119.0, 115.5, 71.5, 66.1, 66.0, 65.0, 62.5, 62.0, 61.0, 60.05, 58.0, 56.5, 49.5, 49.0, 32.5, 31.8, 29.5, 29.0

83

CI MS (M + 1)⁺ 481 (m/z)

mp 165-166°C

Example 52

- 5 4-Fluorophenyl 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-3,7-diaza-
bicyclo[3.3.1]nonane-3-carboxylate

Prepared according to the method described in Example 47 above using 4-fluorophenyl chloroformate, yielding 886 mg (2.02 mmol, 68% yield) of the title compound as a white crystalline solid.

10

¹H NMR (CDCl₃): δ 7.60-7.50 (m, 2H), 7.15-6.88 (m, 6H), 4.51-4.25 (m, 2H), 4.20-3.90 (m, 6H), 3.45-3.00 (m, 4H), 2.65-2.15 (m, 4H), 2.00-1.70 (m, 4H), 1.55 (s, 2H)

15 ¹³C NMR (CDCl₃): δ 161.8, 147.5, 134.0, 123.5, 119.0, 116.0, 115.5, 71.0, 66.0, 65.5, 62.5, 61.8, 60.5, 58.5, 57.0, 50.0, 49.5, 49.0, 43.0, 32.5, 31.5, 29.5, 29.0

CI-MS (M + 1)⁺ 440 (m/z)

mp 145-146°C

20 Example 53

- 4-Methylphenyl 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-3,7-diaza-
bicyclo[3.3.1]nonane-3-carboxylate

Prepared according to the method described in Example 47 above using *p*-tolyl chloroformate, yielding 790 mg (1.81 mmol, 61 % yield) of the title compound as a white crystalline solid.

¹H NMR (CDCl₃): δ 7.60-7.55 (m, 2H), 7.15-6.80 (m, 6H), 4.50-4.30 (m, 2H), 4.20-3.85 (m, 3H), 3.35-3.00 (m, 5H), 2.65-2.15 (m, 7H), 2.00-1.55 (m, 4H)

84

- ¹³C NMR (CDCl₃): δ 162.3, 134.6, 133.9, 133.2, 129.6, 121.5, 119.2, 115.5, 104.0, 70.9, 66.2, 65.5, 62.5, 61.6, 60.3, 59.9, 58.6, 57.3, 49.8, 48.8, 48.7, 32.3, 31.6, 29.5, 29.1, 20.8
CI-MS (M + 1)⁺ 436 (m/z)
5 mp 125-126°C

Example 54

4-Methoxyphenyl 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

10 Prepared according to the method described in Example 47 above using 4-methoxyphenyl chloroformate yielding 655 mg (1.45 mmol; 49% yield) of the title compound as a fine white crystalline solid.

15 ¹H NMR (CDCl₃): δ 7.60-7.45 (m, 2H), 7.10-6.70 (m, 6H), 4.55-4.20 (m, 3H), 4.20-3.85 (m, 4H), 3.75 (d, 3H), 3.60-3.00 (m, 4H), 2.75-1.60 (m, 7H)

20 ¹³C NMR (CDCl₃): δ 162.5, 162.3, 157.1, 155.8, 154.8, 145.2, 134.1, 133.5, 123.5, 122.9, 119.4, 115.7, 114.4, 104.3, 71.1, 66.4, 65.7, 62.7, 61.8, 60.5, 60.3, 58.7, 55.8, 50.0, 49.4, 49.1, 32.5, 31.7, 29.8, 29.4

25 CI-MS (M + 1)⁺ 452 (m/z)
mp 110-111°C

Example 55

(-)Menthyl 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

Prepared according to the method described in Example 47 above using (-)menthyl chloroformate, yielding 270 mg (0.56 mmol; 19% yield) of the title compound as a white crystalline solid.

85

¹H NMR (CDCl₃): δ 7.65-7.50 (d, 2H), 7.05-6.90 (t, 2H), 4.70-3.90 (m, 8H), 3.50-2.85 (m, 5H), 2.60-1.20 (m, 18H), 1.20-0.60 (m, 1H)

¹³C NMR (CDCl₃): δ 162.4, 157.4, 134.0, 119.3, 115.6, 104.1, 75.8, 74.9, 71.4, 71.1, 65.1, 64.9, 62.4, 60.3, 60.1, 56.7, 56.5, 49.7, 48.7, 48.4, 48.3, 47.6, 41.9, 41.5, 34.6, 32.9, 32.8, 31.4, 31.2, 29.7, 29.3, 26.4, 23.7, 23.3, 22.4, 22.2, 21.6, 21.1, 17.0, 16.7

CI-MS (M + 1)⁺ 484 (m/z)

mp 111-112°C

10 Example 56

neo-Pentyl 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-3,7-diazabicyclo-[3.3.1]nonane-3-carboxylate

Prepared according to the method described in Example 47 above using neo-pentyl chloroformate, yielding 960 mg (2.31 mmol; 78% yield) of the title compound as a white crystalline solid.

¹H NMR (CDCl₃): δ 7.60-7.50 (d, 2H), 7.00-6.90 (d, 2H), 4.45-3.60 (m, 8H), 3.30-2.90 (m, 4H), 2.55-2.30 (m, 2H), 2.15-2.00 (m, 2H), 1.90-1.60 (m, 4H), 1.10-0.90 (s, 9H)

20 ¹³C NMR (CDCl₃): δ 162.5, 158.1, 134.1, 119.4, 115.6, 104.3, 75.3, 71.1, 70.7, 66.8, 65.2, 62.9, 62.3, 60.9, 60.4, 58.5, 49.7, 49.0, 48.7, 33.1, 32.1, 31.7, 29.8, 29.6, 26.8

CI-MS (M + 1)⁺ 416 (m/z)

mp 146-147°C

Example 572-Methoxyethyl 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

Prepared according to the method described in Example 47 above using 2-methoxyethyl chloroformate, yielding 420 mg (1.04 mmol, 35% yield) of the title compound as a pale yellow oil.

¹H NMR (CDCl₃): δ 7.60-7.50 (d, 2H), 7.00-6.90 (d, 2H), 4.40-4.10 (m, 5H), 4.05-3.90 (m, 3H), 3.65-3.55 (m, 2H), 3.40-3.35 (s, 3H), 3.30-2.90 (m, 4H), 2.60-2.10 (m, 4H), 1.90-1.60 (m, 4H)

¹³C NMR (CDCl₃): δ 162.4, 157.6, 134.1, 133.4, 119.3, 115.5, 104.3, 71.2, 71.0, 70.7, 66.4, 65.3, 64.6, 62.7, 62.1, 60.8, 60.3, 58.9, 58.2, 56.9, 49.7, 48.9, 32.8, 31.9, 29.8, 29.7, 29.5

CI-MS (M + 1)⁺ 404 (m/z)

15

Example 58tert-Butyl 7-[3-(4-*tert*-butylphenoxy)-2-hydroxypropyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

20 (a) 4-*tert*-Butyl-1-(2-oxiranylmethoxy)benzene

A mixture of epichlorohydrin (15.3 g; 0.165 mol), 4-*tert*-butylphenol (5.0 g; 0.033 mol) and potassium carbonate (6.9 g; 0.050 mol) in acetonitrile (50 mL) was refluxed for 5 h. The resulting heterogeneous mixture was cooled to below reflux temperature and vacuum filtered through fritted glass. The organics were concentrated to give the crude product (7.9 g) as a liquid. Flash chromatography on silica gel (CH₂Cl₂:EtOAc; 19:1) gave the desired product (5.2 g; 76%) as a liquid.

87

¹H NMR (CDCl₃): δ 1.33 (s, 9H), 2.78 (m, 1H), 2.92 (t, 1H), 3.36 (m, 1H), 3.97 (dd, 1H), 4.21 (dd, 1H), 6.88 (d, 2H), 7.32 (d, 2H)

5 (b) tert-Butyl 7-[3-(4-tert-butylphenoxy)-2-hydroxypropyl]-3,7-diaza-
bicyclo[3.3.1]nonane-3-carboxylate

A mixture of *tert*-butyl-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (2.2 g; 9.70 mmol; see Example F above) and 4-*tert*-butyl-1-(2-oxiranylmethoxy)benzene (2.0 g; 9.70 mmol; from step (a) above) in 2-propanol (10 mL) and water (1 mL) was stirred at 60°C for 18 h. The 10 reaction mixture was concentrated to give an oil which was dissolved in hexanes and allowed to stand until solids formed. The solids were collected and dried to give the desired product (0.28 g; 7%) as a white solid.

15 mp 75-77°C

¹H NMR (CDCl₃): δ 1.32 (s, 9H), 1.47 (s, 9H), 1.62-1.78 (m, 2H), 1.79-1.96 (m, 2H), 2.13-2.38 (m, 2H), 2.42-2.57 (m, 2H), 2.87-3.25 (m, 4H), 3.82-4.30 (m, 5H), 6.86 (d, 2H), 7.31 (d, 2H)

20 ¹³C NMR (CDCl₃): δ 28.9, 29.1, 29.4, 29.7, 31.3, 31.7, 32.1, 34.3, 47.9, 48.1, 48.9, 49.6, 57.4, 58.1, 60.6, 61.9, 62.5, 65.5, 65.9, 70.7, 77.4, 79.7, 114.3, 126.4, 143.6, 155.8, 156.2, 156.8

CI-MS (M + 1)⁺ 433 (m/z)

Example 59tert-Butyl 7-[3-(phenoxy)-2-hydroxypropyl]-3,7-diazabicyclo[3.3.1]-nonane-3-carboxylate5 (a) 1-(2-Oxiranylmethoxy)benzene

Prepared according to the method described in Example 58(a) above using phenol (5.0 g; 0.053 mol), yielding 7.8 g (98%) of the sub-title compound as a liquid.

10 ^1H NMR (CDCl_3): δ 2.77 (m, 1H), 2.90 (t, 1H), 3.37 (m, 1H), 3.98 (dd, 1H), 4.24 (dd, 1H), 6.87-7.03 (m, 3H), 7.22-7.35 (m, 2H)

(b) tert-Butyl 7-[3-(phenoxy)-2-hydroxypropyl]-3,7-diazabicyclo[3.3.1]-nonane-3-carboxylate

15 Prepared according to the method described in Example 58(b) above from 1-(2-oxiranylmethoxy)benzene (2.0 g; 13.3 mmol; from step (a) above), yielding 2.4 g (48%) of the sub-title compound as a white solid.

mp 86-88°C

20 ^1H NMR (CDCl_3): δ 1.47 (s, 9H), 1.58-1.97 (m, 4H), 2.14-2.38 (m, 2H), 2.43-2.58 (m, 2H), 2.87-3.26 (m, 4H), 3.84-4.32 (m, 5H), 6.89-6.98 (m, 3H), 7.22-7.33 (m, 2H)

^{13}C NMR (CDCl_3) δ 28.9, 29.1, 29.3, 29.6, 31.3, 32.1, 47.9, 48.8, 49.6, 57.4, 58.1, 60.5, 61.8, 62.3, 65.5, 65.8, 70.6, 79.6, 114.8, 120.9,

25 129.5, 155.6, 156.0, 159.1

CI-MS ($M + 1$)⁺ 377 (m/z)

Example 60*tert*-Butyl-7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-9,9-dimethyl-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate5 (a) Ethyl (2,2'-dimethylidene)cynoacetate

A mixture of acetone (30.8 g; 0.530 mol), ethyl cyanoacetate (50.0 g; 0.442 mol), ammonium acetate (6.80 g; 88.4 mmol), and glacial acetic acid (21.2 g; 0.354 mol) in benzene (100 mL) was heated under reflux for 9 h with azeotropic removal of water. The mixture was washed with 10 water (3 x 50 mL), and the aqueous layer was extracted with ethyl acetate (50 mL). The combined organic extracts were dried over Na_2SO_4 , and evaporated to an orange oil which was distilled under vacuum at 70-75°C at 0.5 mm Hg to afford the sub-title compound (43.1 g; 64%) as a colourless liquid.

15

^1H NMR (CDCl_3) δ 4.20 (q, $J=7.9$ Hz, 2H), 2.33 (s, 3H), 2.25 (s, 3H), 1.30 (t, $J=7.9$ Hz, 3H)

(b) 1-Benzyl-3,5-dicyano-4,4-dimethyl-2,6-dioxopiperidone

20 Sodium metal (6.1 g; 0.264 mol) was added in pieces to absolute ethanol (375 mL) at 25°C under nitrogen. After all the sodium had been dissolved, *N*-(cyanoacetyl) benzylamide (46.9 g; 0.270 mol; see Example 40(a) above) and ethyl (2,2'-dimethylidene)cynoacetate (41.3 g; 0.270 mol; from step (a) above) were added sequentially. The dark orange 25 mixture was stirred 3 days at 25°C, poured into water (300 mL), and concentrated hydrochloric acid (100 mL) was then added, following which a solid precipitated. The solid was collected *via* filtration over a sintered-glass funnel to yield the sub-title compound (39.5 g, 52%) as a tan solid.

90

mp 140-145°C

¹H NMR (DMSO-d₆): δ 7.20-7.38 (m, 5H), 5.08 (s, 2H), 4.90 (s, 2H), 1.37 (s, 3H), 1.18 (s, 3H)

5 (c) 3-Benzyl-9,9-dimethyl-3,7-diazabicyclo[3.3.1]nonane-2,4,6,8-tetraone

A mixture of 1-benzyl-3,5-dicyano-4,4-dimethyl-2,6-dioxopiperidone (9.5 g; 43.5 mmol; from step (b) above) in phosphoric acid (50 mL) and sulfuric acid (50 mL) was heated at 120°C for 1 h. The mixture was cooled and poured into ice-water (100 mL). The mixture was extracted with chloroform (3 x 100 mL), dried over Na₂SO₄, and evaporated to a white residue which was recrystallized from methanol to afford the sub-title compound (980 mg; 8%) as a white solid.

10 mp 243-245°C

15 ¹H NMR (CDCl₃): δ 7.22-7.37 (m, 3H), 7.10-7.18 (m, 2H), 4.82 (s, 2H), 3.83 (s, 2H), 1.12 (s, 3H), 1.08 (s, 3H)

(d) 3-Benzyl-9,9-dimethyl-3,7-diazabicyclo[3.3.1]nonane

A solution of 3-benzyl-9,9-dimethyl-3,7-diazabicyclo[3.3.1]nonane-2,4,6,8-tetraone (980 mg; 3.26 mmol; from step (c) above) in 1,4-dioxane (25 mL) was added dropwise to a suspension of lithium aluminium hydride (990 mg; 26.1 mmol) in 1,4-dioxane (30 mL) at 0°C. The mixture was refluxed overnight, cooled to 0°C whereafter water (1.0 mL), 15% aqueous sodium hydroxide (1.0 mL), and more water (3.0 mL), were added sequentially. After stirring for 1 h at 0°C, the mixture was filtered through a small pad of Celite, washing the Celite cake with ethyl acetate (100 mL). The filtrate was evaporated to give the sub-title compound (676 mg; 85% crude yield) as a colourless oil which was used directly in the next step without further purification.

¹H NMR (CDCl₃): δ 7.15-7.38 (m, 5H), 3.52-3.80 (m, 2H), 3.40 (s, 2H), 3.18-3.30 (m, 2H), 2.53-2.89 (m, 5H), 1.10-1.32 (m, 2H), 1.14 (s, 3H), 1.10 (s, 3H)

5 ¹³C NMR (CDCl₃): δ 138.8, 128.6, 128.3, 126.9, 77.4, 63.6, 55.0, 48.5, 39.5, 26.8, 26.1

CI-MS (M + 1)⁺ 245 (m/z)

10 (e) tert-Butyl-7-benzyl-9,9-dimethyl-3,7-diazabicycl[3.3.1]nonane-3-carboxylate

A mixture of 3-benzyl-9,9-dimethyl-3,7-diazabicyclo[3.3.1]nonane (650 mg, 2.66 mmol; from step (d) above) and di-*tert*-butyl dicarbonate (580 mg; 2.66 mmol) in THF (8.0 mL) was stirred for 3 hours at 25°C. The mixture was evaporated to afford the sub-title compound (940 mg; 104% 15 crude yield) as pale yellow oil which was used directly in the next step without further purification.

20 ¹H NMR (CDCl₃): δ 7.18-7.40 (m, 5H), 3.84-3.96 (m, 2H), 3.66-3.77 (m, 1H), 3.35-3.60 (m, 4H), 2.57-2.75 (m, 4H), 1.50 (s, 9H), 1.25-1.43 (m, 2H), 1.08 (s, 6H)

25 ¹³C NMR (CDCl₃): δ 173.8, 155.2, 139.4, 128.3, 128.1, 126.6, 78.7, 62.6, 55.4, 54.8, 46.5, 46.0, 38.5, 30.0, 28.7, 27.4, 25.6

CI-MS (M + 1)⁺ 345 (m/z)

25 (f) tert-Butyl-9,9-dimethyl-3,7-diazabicycl[3.3.1]nonane-3-carboxylate

A mixture of *tert*-butyl-7-benzyl-9,9-dimethyl-3,7-diazabicycl[3.3.1]-nonane-3-carboxylate (900 mg; 2.61 mmol; from step (e) above) and 10% palladium on carbon (w/w; 90 mg) in absolute ethanol (12 mL) was stirred overnight under 1 atmosphere of hydrogen. The catalyst was removed by

92

filtration through a pad of Celite washing the Celite with ethyl acetate (50 mL). The filtrate was concentrated to an oil which was chromatographed on silica gel eluting with methanol:methylene chloride (1:10) to yield the sub-title compound (326 mg, 50%) as a pale yellow oil.

5

¹H NMR (CDCl₃): δ 3.68-3.83 (m, 2H), 3.37-3.48 (m, 2H), 3.15-3.29 (m, 2H), 2.80-2.90 (m, 2H), 2.56 (bs, 1H), 1.40 (s, 9H), 1.18-1.30 (m, 2H), 1.14 (s, 3H), 1.04 (s, 3H)

¹³C NMR (CDCl₃): δ 155.6, 79.7, 48.3, 37.8, 30.3, 28.5, 26.9, 25.7,

10 24.4

CI-MS (M + 1)⁺ 255 (m/z)

(g) tert-Butyl-7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-9,9-dimethyl-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

15 A mixture of *tert*-butyl-9,9-dimethyl-3,7-diazabicycl[3.3.1]nonane-3-carboxylate (306 mg; 1.20 mmol; from step (f) above) and 4-(2-oxiranylmethoxy)benzonitrile (211 mg; 1.20 mmol; see Example A above) in isopropanol:water (2.0 mL; 9:1) was heated at 60°C for 20 h. The mixture was concentrated to an oil which was partitioned with water (15 mL) and methylene chloride (2 x 20 mL). The organic layer was separated, dried over Na₂SO₄, and evaporated to an oil which was chromatographed on silica gel eluting with methylene chloride:methanol (98:2). Fractions containing the desired product were combined and concentrated to afford the title compound (220 mg; 43%) as a colourless
20 oil.
25

¹H NMR (CDCl₃): δ 7.55 (d, J=9.7 Hz, 2H), 6.97 (d, J=9.7 Hz), 3.71-3.99 (m, 8H), 2.42-2.99 (m, 6H), 1.45-1.50 (m, 2H), 1.42 (s, 9H), 1.13 (s, 6H)

93

¹³C NMR (CDCl₃): δ 162.0, 155.5, 133.7, 118.9, 115.3, 103.8, 79.1, 70.5, 65.2, 60.5, 60.0, 56.5, 53.8, 53.2, 46.3, 38.2, 38.0, 28.3, 25.8, 25.4

CI-MS (M + 1)⁺ 430 (m/z)

5

Example 61

tert-Butyl-7-[[3-(4-cyanophenoxy)-1,1-dimethyl-2-hydroxy]propyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

10 (a) 2,3-Oxiranyl-3-methyl-1-butanol

mCPBA (56%; 33.75 g; 1.1 eq.) was added to a solution of 3-methyl-2-butene-1-ol (8.6 g; 100 mmol; 10.2 mL) in chloroform (500 mL) at 0°C, and the solution was stirred for 10 min. at 0°C. The reaction was then stirred at room temperature for 40 minutes, quenched with saturated K₂CO₃ solution (200 g) and stirred for 2 h.. The organic layer was separated, dried over K₂CO₃, and concentrated *in vacuo* to give a clear, colourless oil (8.6 g, 84%). The oil was used immediately in the next step.

20 ¹H NMR (CDCl₃): δ 3.87 (dd, 1H), 3.67 (dd, 1H), 3.00 (m, 1H), 1.37 (s, 3H), 1.32 (s, 3H)

(b) 2,3-Oxiranyl-3-methyl-1-butyl p-toluenesulfonate

A solution of tosyl chloride (20.7 g; 110 mmol) in CH₂Cl₂ (300 mL) was 25 added dropwise to a 0°C solution of 2,3-oxiranyl-3-methyl-1-butanol (8.60 g; 84.3 mmol; from step (a) above) and triethylamine (21 mL; 150 mmol) in CH₂Cl₂ (300 mL). The reaction was stirred at 0°C for 1 h and stored in a freezer at -10°C for 36 h. Intermittently, the reaction vessel was removed from the freezer, shaken and then placed back into the freezer.

94

The reaction mixture was washed with brine (250 mL) and the CH₂Cl₂ layer was separated. The aqueous layer was extracted with CH₂Cl₂ (4 x 75 mL). The combined organic layers were dried over Na₂SO₄ and concentrated *in vacuo* to give an orange residue. The residue was subjected to column chromatography on silica gel eluting with a gradient of EtOAc in hexane (1:9 to 1:4). Fractions containing the desired compound were combined and concentrated to afford 21.34 g (98%) of a colourless oil.

10 ¹H NMR (CDCl₃): δ 7.82 (d, 2H), 7.37 (d, 2H), 4.13 (m, 2H), 2.98 (m, 1H), 2.46 (s, 3H), 1.31 (s, 3H), 1.23 (s, 3H)

(c) 4-(3-Methyl-2,3-oxiranylbutoxy)benzonitrile

A solution of 4-cyanophenol (10.41 g; 87 mmol) in dry DMF (100 mL) was added dropwise to a suspension of sodium hydride (2.08 g; 87 mmol) in dry DMF (200 mL). The solution was stirred for 1 h at room temperature followed by the addition of a solution of 2,3-oxiranyl-3-methyl-1-butyl *p*-toluenesulfonate (21.34 g; 83 mmol; from step (b) above) in dry DMF (100 mL). The reaction was stirred at room temperature overnight. The reaction mixture was carefully poured into ice cold H₂O (400 mL) followed by extraction with CHCl₃ (1 x 500 mL, 3 x 100 mL). The combined organic extracts were dried over Na₂SO₄ and concentrated *in vacuo* to afford an off white solid. The desired product was then isolated *via* crystallization from isopropyl ether (8.88 g, 53%).

25

¹H NMR (CDCl₃): δ 7.60 (d, 2H), 7.00 (d, 2H), 4.23 (dd, 1H), 4.09 (dd, 1H), 3.15 (m, 1H), 1.42 (s, 3H), 1.39 (s, 3H)

95

(d) tert-Butyl-7-[[3-(4-cyanophenoxy)-1,1-dimethyl-2-hydroxy]propyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

A mixture of 4-(3-methyl-2,3-oxiranylbutoxy)benzonitrile (0.956 g; 4.70 mmol; from step (c) above) and *tert*-butyl-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (1.06 g; 4.70 mmol; see Example F) was refluxed in *iso*-propanol:H₂O (10:1; 10 mL) for 5 days. The reaction mixture was concentrated *in vacuo*. The residue was dissolved in CH₂Cl₂ (150 mL), washed with water (50 mL), brine (50 mL), dried over Na₂SO₄ and concentrated *in vacuo* to afford a light yellow oil. Purification *via* column chromatography on silica gel eluting with CH₂Cl₂:CH₃OH (80:1) gave 0.540 g (27%) of the title compound.

R_f 0.43 (CH₂Cl₂:CH₃OH (25:1))

¹H NMR (CDCl₃) δ 7.61 (d, 2H), 6.98 (d, 2H), 3.88-4.62 (m, 5H), 3.65 (brs, 1H), 2.89-3.33 (m, 6H), 2.78 (m, 2H), 1.66 (brs, 1H), 1.48 (s, 9H), 1.26 (s, 3H), 1.17 (s, 3H)

CI-MS (M + 1)⁺ 430 (m/z)

Example 62

20 tert-Butyl 7-[3-(4-cyano-2-hydroxyphenoxy)propyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

(a) 4-(3-Chloropropoxy)-3-hydroxybenzonitrile

NaH (0.20 g; 8.14 mmol) was added to a room temperature solution of 25 3,4-dihydroxybenzonitrile (1.00 g; 7.40 mmol) in DMF. After stirring for 15 minutes, 1-bromo-3-chloropropane (1.3 g; 8.14 mmol) was added to the mixture. The reaction was stirred for 40 h at room temperature, and then quenched with water and extracted with EtOAc (100 mL). The EtOAc extract was washed with brine (4 x 100 mL), dried over Na₂SO₄

96

and concentrated *in vacuo*. The resulting crude product was chromatographed on a column of silica (5 cm x 18 cm) eluting with a mixture of EtOAc and hexanes (1:4). Fractions containing the desired product were combined and concentrated *in vacuo* to afford the sub-title compound as an oil (0.5 g; 32%).

CI-MS (M + 1)⁺ 212 (m/z)

¹H NMR (CDCl₃): δ 2.34 (m, 2H), 3.78 (t, 2H), 4.25 (t, 2H), 6.37 (br s, 1H), 6.92 (d, 1H), 7.17 (m, 2H)

10

(b) tert-Butyl 7-[3-(4-cyano-2-hydroxyphenoxy)propyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

A solution of 4-(3-chloropropoxy)-3-hydroxybenzonitrile (0.50 g; 2.36 mmol; from step (a) above) and *tert*-butyl 3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (0.80 g; 3.54 mmol; see Example F above) in acetonitrile (20 mL) was stirred for 20 h at 47°C. The reaction was concentrated *in vacuo* and the residue chromatographed on a column of silica (4 cm x 24 cm) eluting with a mixture of CH₂Cl₂ and CH₃OH (98:2). After eluting 1 litre of the above eluant, the ratio of CH₂Cl₂ to CH₃OH was changed to 95:5. Fractions containing the desired product were combined and concentrated *in vacuo* to afford 0.49 g of a semi-solid. This material was slurried with hexane to afford the title compound as an off white solid (0.40 g; 42%).

25 mp 127-130°C

CI-MS (M + 1)⁺ 402 (m/z)

¹H NMR (CDCl₃): δ 1.42 (s, 9H), 1.65 (br s, 2H), 1.92 (m, 4H), 2.25 (m, 4H), 3.01 (m, 4H), 4.12 (m, 4H), 6.91 (d, 1H), 7.18 (m, 2H)

⁹⁷

¹³C NMR (CDCl₃): δ 26.2, 28.5, 31.2, 47.9, 49.2, 55.1, 58.2, 59.1, 67.5, 79.6, 104.2, 102.5, 118.2, 119.5, 125.3, 146.8, 150.5, 155.8

Example 63

5 tert-Butyl 7-[4-(4-cyanophenyl)-2-hydroxybutyl]-3,7-diazabicyclo[3.3.1]-nonane-3-carboxylate

(a) 4-(3-Butenyl)benzonitrile

ZnCl₂ (15.0 g; 110 mmol) was heated with a blow torch under vacuum
10 until fused for about 20 min. After cooling to room temperature,
magnesium turnings (2.7 g; 110 mmol) were added and heated again until
ZnCl₂ was partially fused again (ca. 5 min). The mixture was cooled to
room temperature, placed under N₂ and dry THF (100 mL) was added. 4-
Bromo-1-butene (11.0 mL; 110 mmol) was then added and the mixture
15 was treated with sonication and warming for 2 h followed by stirring at
room temperature for 1.5 days. Pd(Ph₃P)₄ (6.00 g; 5.19 mmol) in THF
(60 mL) was added to this mixture, followed by 4-bromobenzonitrile (20.0
g; 110 mmol) in THF (100 mL). The mixture was stirred for 24 h at
room temperature. The reaction was quenched by the addition of 3N HCl
20 (500 mL) and extracted with ether (2 x 400 mL). The organic layer was
dried over MgSO₄, filtered and evaporated to give 20.1 g of an oil/solid
mixture. The residue was purified on a wet-packed silica gel column (6.5
x 40 cm; 10% EtOAc/Hex) eluting with 10% EtOAc/hexanes. After a
500 mL forerun, 200 mL fractions were collected. Fractions 3-6 were
25 combined and evaporated to give 13.6 g (79%) of a clear semi-solid.
Analysis by ¹H NMR showed the sub-title product and 4-
bromobenzonitrile (in a 2.2/1 ratio (approximately)). This material was
used directly in the next step.

(b) 4-(3-Oxiranylbutyl)benzonitrile

*m*CPBA (49.0 g; 288 mmol) was added to a solution of the product from step (a) above; 13.6 g; 57.7 mmol) in CH₂Cl₂ (550 mL). The solution was stirred at room temperature for 2 days. To this solution was added 5 CH₂Cl₂ (200 mL) and the organic layer was washed with saturated NaHCO₃ (500 mL), 10% Na₂S₂O₃ (2 x 400 mL), saturated NaHCO₃ (400 mL) and brine (200 mL). The organic layer was then dried over MgSO₄, filtered and evaporated to give 13.9 g of a semi-solid. Analysis by ¹H NMR showed the presence of the sub-title product and 4-bromobenzonitrile. This material was used directly in the next step.
10

(c) tert-Butyl 7-[4-(4-cyanophenyl)-2-hydroxybutyl]-3,7-diazabicyclo-[3.3.1]nonane-3-carboxylate

The product mixture from step (b) above (400 mg; 2.31 mmol) was heated 15 in the presence of *tert*-butyl 3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (374 mg; 1.65 mmol; see Example F above) in 2-propanol (5 mL) at 60°C for 7 h. The solution was stirred at room temperature for 2 days. The solvent was evaporated and the residue chromatographed on a wet-packed silica gel column (3.5 x 24 cm, 1:1 EtOAc/hexane) eluting with 20 EtOAc:hexane (1:1). After a 50 mL forerun, 15 mL fractions were collected. Fractions 66-70 were combined and evaporated to give 433 mg (66%) of the title product as an off-white solid.

mp 88-93°C

25 CI-MS (M + 1)⁺ 400 (m/z)

¹H NMR (CDCl₃): δ 7.56 (d, J=8.2 Hz, 2 H), 7.31 (d, J=8.2 Hz, 2 H), 3.99- 4.25 (m, 2 H), 3.60-3.69 (m, 1 H), 3.5 (br s, 1 H), 2.69-3.15 (m, 6 H), 2.47 (m, 1 H), 1.75-2.4 (m, 6 H), 1.54-1.72 (m, 3 H) 1.47 (s, 9 H)

99

¹³C NMR (CDCl₃): δ 148.5, 132.3, 129.5, 119.3, 109.7, 79.6, 65.6, 65.2, 60.7, 57.7, 57.1, 49.5, 48.8, 47.8, 36.2, 32.2, 32.1, 31.4, 29.6, 29.0, 28.9

5 Example 64

tert-Butyl 7-[4-(4-cyanophenoxy)-2-hydroxybutyl]-3,7-diazabicyclo[3.3.1]-nonane-3-carboxylate

(a) 4-(2-Oxiranylethoxy)benzonitrile

10 mCPBA (15.9 g; 65 mmol) was added to a stirred solution of 4-(4'-cyanophenoxy)but-1-ene (7.5 g; 56 mmol; prepared according to the method described in J. Chem. Soc. Perkin Trans. 1, 9 (1992) 1145-1148) in CH₂Cl₂ (175 mL) and the reaction mixture was stirred at room temperature for 4 h. The reaction mixture was washed with NaHCO₃ (aq.) and the organic layer separated, dried and concentrated to give the subtitle compound (7.23 g; 38 mmol).

(b) tert-Butyl 7-[4-(4-cyanophenoxy)-2-hydroxybutyl]-3,7-diazabicyclo-[3.3.1]nonane-3-carboxylate

20 4-(2-Oxiranylethoxy)benzonitrile (0.946 g; 5.0 mmol; from step (a) above) was added to a stirred solution of *tert*-butyl 3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (1.13 g; 5.0 mmol; see Example F above) in MeCN (50 mL) and the reaction mixture was stirred at 75°C for 72 h. The reaction mixture was concentrated and the residue subjected to column chromatography (CH₂Cl₂:MeOH; 15:1) to give the title compound in a 88% yield (1.84 g; 4.42 mmol).

FAB-MS (M + 1)⁺ 416 (m/z)

¹⁰⁰
¹³C NMR (CDCl₃): δ 28.74, 29.53, 32.22, 34.31, 47.13, 49.44, 56.92, 60.45, 62.89, 65.38, 79.96, 104.01, 115.22, 119.36, 134.03, 156.06, 162.41

5 Example 65

tert-Butyl 7-{3-[{(4-cyanophenyl)thio]-2-hydroxypropyl}-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

The title compound was prepared according to the procedure described in Example 64 above using (4-cyanophenylsulfonylmethyl)oxirane (prepared 10 according to the method described in Example A above from *p*-cyanothiophenol).

FAB-MS: (M + 1)⁺ 418 (m/z)

¹³C NMR (CDCl₃): δ 29.79, 30.54, 33.10, 37.80, 48.70, 50.52, 58.05, 15 59.07, 61.32, 65.12, 66.36, 80.66, 109.24, 120.03, 128.08, 133.18, 146.14, 156.93

Example 66

tert-Butyl 7-[4-(4-cyanophenoxy)-2-butenyl]-3,7-diazabicyclo[3.3.1]-20 nonane-3-carboxylate

(a) 4-(4-Cyanophenoxy)-1-chloro-2-butene

1,4-Dichlorobutene (750 g; 5 mol) was added to a stirred suspension of 4-cyanophenol (119.12 g; 1 mol) and K₂CO₃ (345 g; 2.5 mol) in MeCN (1000 mL) and the reaction mixture was refluxed for 4 h. The reaction 25 mixture was filtered and concentrated. The residue was dissolved in di-*iso*-propyl ether (2000 mL) and after 24 h the precipitate was filtered off. The filtrate was concentrated giving the sub-title compound as a yellow oil which solidified upon standing (186 g; 0.89 mol).

(b) tert-Butyl 7-[4-(4-cyanophenoxy)-2-butenyl]-3,7-diazabicyclo[3.3.1]-nonane-3-carboxylate

tert-Butyl 3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (1.13 g; 5 mmol; see Example F above) was added to a stirred solution of 4-(4-cyanophenoxy)-1-chloro-2-butene (1.04 g; 5 mmol; from step (a) above) in MeCN (25 mL) and the reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated and partitioned between diethyl ether and KHSO₄ (0.3 M). The aqueous layer was treated with NaOH (2M) and subsequently extracted with CH₂Cl₂. The organic layer was washed with water, dried, concentrated and purified using column chromatography (CH₂Cl₂:MeOH; 95:5) to give the title compound (0.84 g; 2.1 mmol).

13C NMR (CDCl₃): δ 28.75, 32.18, 47.90, 49.04, 58.19, 59.05, 60.76, 68.77, 78.49, 103.93, 115.65, 119.37, 125.66, 133.95, 155.39, 161.96

Example 67

20 tert-Butyl 7-{2-[2-(4-cyanophenoxy)ethoxy]ethyl}-3,7-diazabicyclo-[3.3.1]nonane-3-carboxylate

(a) 4-(2-Bromoethoxy)benzonitrile

The sub-title compound was prepared according to the method described in J. Chem. Soc., (1942) 103, 114, but using K₂CO₃ as the base.

25

(b) 2-(4-Cyanophenoxy)ethoxyethanol

Ethylene glycol (12 mL, 220 mmol) was added to a suspension of NaH (2.8 g; 66 mmol) in DMF (10 mL) and the reaction mixture was stirred for 10 minutes. 4-(2-Bromoethoxy)benzonitrile (5 g; 22 mmol; from step

102

(a) above) was added and the reaction mixture was stirred at 80°C for 3 h and then overnight at room temperature. The reaction mixture was filtered and subjected to column chromatography (hexane:EtOAc; 1:1) giving the sub-title compound in 50% yield.

5

(c) tert-Butyl 7-[2-[2-(4-cyanophenoxy)ethoxy]ethyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

Mesylchloride (2.9 g; 29 mmol) was added to a stirred -5°C solution of 2-(4-cyanophenoxy)ethoxy]ethanol (5.0 g; 24 mmol; from step (b) above) in CH₂Cl₂ (50 mL) and the reaction mixture was stirred at room temperature for 2 h. The reaction mixture was washed with H₂O and the organic layer separated, dried and concentrated. Part of the oily residue (2.0 g; 7 mmol) was dissolved in MeCN (50 mL) and K₂CO₃ (1.5 g; 10.5 mmol) and *tert*-butyl 3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (1.6 g; 7.0 mmol; see Example F above) were added. The suspension was refluxed overnight and the salts were filtered off. The filtrate was concentrated and purified using column chromatography (EtOAc) giving the title compound (1.0 g; 2.4 mmol).

20 ESI-MS (M+1)⁺ 417 (m/z)

¹³C NMR (CDCl₃): δ 28.66, 29.13, 31.54, 47.74, 48.88, 58.15, 58.72, 59.54, 67.73, 69.07, 69.90, 78.51, 104.01, 115.35, 119.24, 133.93, 155.2

Example 68*tert*-Butyl 7-[4-(4-cyanophenyl)butyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate5 (a) 2-[2-(4-Cyanophenoxy)ethyl]malonic acid dimethyl ether

NaH (3.05 g; 127 mmol) was added at 0°C to a stirred solution of malonic acid dimethyl ester (17 g; 129 mmol) in MeCN (225 mL). A solution of 4-cyanophenethyl methanesulfonate (9.7 g; 43.1 mmol; see Example 25(a) above) in MeCN (50 mL) was added and the reaction mixture was refluxed overnight. NaHCO₃ (3 g) was added and the slurry was filtered and concentrated. The residue was partitioned between diethyl ether and H₂O and the organic layer was separated, dried and concentrated. The residue was purified using column chromatography (toluene:di-*iso*-propyl ether; 1:3) giving the sub-title compound (14.6 g; contaminated with malonic acid dimethyl ester). This product was used directly in the next step without further purification.

(b) 4-(4-Cyanophenoxy)butyric acid methyl ester

A mixture of 2-[2-(4-cyanophenoxy)ethyl]malonic acid dimethyl ether (11.07 g; 42.4 mmol; from step (a) above), NaCl (2.64 g; 45 mmol), H₂O (1.62 g; 90 mmol) and DMSO (35 mL) was refluxed for 36 h. H₂O (400 mL) was added and the mixture was extracted with diethyl ether. The organic layer was washed with H₂O, dried and concentrated. Purification using column chromatography (toluene:di-*iso*-propyl ether; 1:3) gave the sub-title compound (5.04 g; 24.8 mmol).

(c) 4-(4-Cyanophenoxy)-1-butanol

LiBH₄ (1.5 g; 71.1 mmol) was added to a stirred solution of 4-(4-cyanophenoxy)butyric acid methyl ester (9.63 g; 47.4 mmol; from step (b)

104

above), MeOH (2.87 mL; 71.1 mmol) and diethyl ether (158 mL) and the reaction mixture was refluxed overnight. The ether phase was collected and the residue was extracted with diethyl ether (3 x 50 mL). The combined organic phase was dried, concentrated and purified using 5 column chromatography (EtOAc:hexane; 1:3) to give the sub-title compound (3.82 g; 21.8 mmol).

15 (d) Methanesulfonic acid 4-(4-cyanophenoxy)-butyl ester

10 Mesylchloride (2.32 mL; 30 mmol) was added to a stirred 0°C solution of 4-(4-cyanophenoxy)-1-butanol (5.2 g; 29.7 mmol; from step (c) above) and TEA (4.35 mL) in CH₂Cl₂ (50 mL), and the reaction mixture was stirred for 4 h. H₂O (150 mL) was added and the organic layer separated, dried and concentrated to give the sub-title compound which was used without further purification.

15

(e) tert-Butyl 7-[4-(4-cyanophenyl)butyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate

20 The title compound was prepared in 73% yield from methanesulfonic acid 4-(4-cyanophenoxy)-butyl ester and *tert*-butyl 3,7-diazabicyclo[3.3.1]-nonane-3-carboxylate (from step (d) above) according to the method described in Example 25(b) above.

25 ¹³C NMR (CDCl₃): δ 26.23, 28.72, 29.09, 31.56, 36.01, 47.67, 48.72, 58.31, 58.81, 59.19, 78.39, 109.38, 119.19, 129.17, 129.42, 131.91, 132.16, 148.41, 155.05

Example 697-[2-(4-Cyanophenoxy)ethyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylic acid *tert*-butyl ester

5 *tert*-Butyl-3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (3.62 g; 16 mmol; see Example F above) was added to a stirred solution of 4-(2-bromoethoxy)benzonitrile (3.62 g; 16 mmol; see Example 67(a) above) and TEA (3.34 mL; 24 mmol) in MeCN (70 mL) and the reaction mixture was stirred at 60°C overnight and then stored at room temperature for 48 h. The solids were filtered off, washed with IPA (2 x 100 mL) and the filtrate concentrated. The residue was partitioned between DCM and NaHCO₃ (sat.), the organic layer was separated, dried (MgSO₄) and concentrated. The oily residue was subjected to column chromatography (DCM:MeOH; 25:1) to give the title compound in a 72% yield.

15 ¹³C NMR (CDCl₃): δ 29.73, 30.25, 30.44, 32.73, 48.83, 50.00, 58.24, 59.71, 60.48, 68.04, 79.67, 104.48, 116.37, 120.65, 135.04, 156.35, 163.23

Example 70

20 Methyl 7-[3-(4-cyanophenoxy)-2-hydroxypropyl]-3,7-diazabicyclo[3.3.1]-nonane-3-carboxylate

The title compound was prepared according to the method described in Example 1 above, starting with methylchloroformate.

25 Example 71

7-[2-(4-Cyanophenoxy)-2-hydroxypropyl]-3,7-diazabicyclo[3.3.1]-nonane-3-carboxylic acid 1-*tert*-butoxycarbonyl-piperidine-4-yl ester

N-(*tert*-Butyloxycarbonyl)-4-piperidinol (470 mg; 2.3 mmol; see Tetrahedron Lett.; 37; 36 (1996) 6439-6442) was added to a stirred

106

solution of carbonyl diimidazole (379 mg; 2.3 mmol) in MeCN, and the reaction mixture was stirred for 48 h. 4-[3-(3,7-Diazabicyclo[3.3.1]non-3-yl)-2-hydroxypropoxylbenzonitrile (692 mg; 2.3 mmol; see Example G above) was added in one portion and the reaction mixture was refluxed for 5 2 h. The solvent was removed on a rotary evaporator and the residue partitioned between DCM and NaHCO₃ (sat.). The organic layer was collected, dried, concentrated and purified using column chromatography (DCM:MeOH; 25:1) to give the title compound in a 74% yield.

10 ¹³C NMR (CDCl₃): δ 29.51, 30.23, 30.52, 32.05, 33.75, 49.66, 50.60, 54.53, 57.56, 59.45, 61.26, 61.84, 62.56, 63.47, 65.98, 67.27, 71.04, 71.51, 71.92, 80.59, 106.52, 116.42, 120.25, 134.98, 155.84, 157.74, 163.26

FAB-MS: (M+1)⁺ 529.1 (m/z)

15

Example 72

7-[3-(4-Cyanophenoxy)-2(S)-hydroxypropyl]-3,7-diazabicyclo[3.3.1]-nonane-3-carboxylic acid cyclopropylmethyl ester

A cooled solution of cyclopropanemethanol (1.8 g; 25 mmol) in THF (7 mL) was added to a stirred 0°C dispersion of CDI (4.05 g; 25 mmol) in THF (15 mL), and the reaction mixture was stirred for 30 minutes. A fraction of this solution (3.75 mL; 4.35 mmol) was added to a dispersion of 4-[3-(3,7-diazabicyclo[3.3.1]non-3-yl)-2(S)-hydroxypropoxy]benzonitrile (2.25 g; 6.0 mmol; dihydrochloride salt; prepared from 3,7-diazabicyclo[3.3.1]nonane-3-carboxylic acid and 7-[(2S)-3-(4-cyanophenoxy)-2-hydroxypropyl]-1,1-dimethylethyl ester, analogously to the method described in Example G above) and K₂CO₃ (2.0 g; 14.5 mmol) in THF (10 mL). The reaction mixture was heated (85°C) in a sealed steel vessel for 24 hours, was then concentrated, and the residue partitioned

107

between DCM and water. The organic layer was collected, dried, concentrated and subjected to column chromatography (DCM:MeOH; 95:5) to give the title compound in a 29% yield.

5 FAB-MS ($M + I$)⁺ 400.0 (m/z)

Example 73

7-[3-(4-Cyanophenoxy)-2-hydroxypropyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylic acid 2-(4-acetylpirazin-1-yl) ethyl ester

10

(a) 1-[4-(2-Hydroxyethyl)piperazin-1-yl]ethanone

Acetic acid anhydride (5.1 g; 50 mmol) was added to a stirred solution of N-(2-hydroxyethyl)piperazine (6.5 g; 50 mmol) in DCM (5 mL). The reaction mixture was stirred until the exothermic reaction was complete.

15 The solvent was evaporated and the residue co-evaporated with toluene. The crude sub-title compound was used without further purification.

(b) 7-[3-(4-Cyanophenoxy)-2-hydroxypropyl]-3,7-diazabicyclo[3.3.1]-nonane-3-carboxylic acid 2-(4-acetylpirazin-1-yl) ethyl ester

20 A solution of CDI (0.5 g; 3.1 mmol) in DCM (20 mL) was added to a stirred solution of 1-[4-(2-hydroxyethyl)-piperazin-1-yl]ethanone (0.5 g; 2.9 mmol; from step (a) above) in DCM (5 mL), and the reaction mixture was stirred for 1 hour. Water was added and the organic layer collected, dried and concentrated to give the imidazolide in a 80% yield. A solution of 4-[3-(3,7-diazabicyclo[3.3.1]non-3-yl)-2-hydroxypropoxy]benzonitrile (375 mg; 1.25 mmol; see Example G above) in MeCN (25 mL) was added to a portion of the imidazolide (333 mg; 1.25 mmol) and KCO₃ (s) in MeCN (10 mL), and the reaction mixture was stirred for 15 hours. The solvent was removed on a rotary evaporator and the residue partitioned

108

between DCM and water. The organic layer was collected, dried, concentrated and subjected to column chromatography (DCM:MeOH; 95:5) to give the title compound in a 35% yield.

5 FAB-MS ($M + I$)⁺ 499.4 (m/z)

Example 74

7-[3-(4-Cyanophenoxy)-2-hydroxy-2-hydroxymethylpropyl]-3,7-diaza-bicyclo[3.3.1]nonane-3-carboxylic acid *tert*-butyl ester

10

(a) 4-(2-Chloromethylallyloxy)benzonitrile

A solution of 4-cyanophenol (11.9 g; 0.1 mol) in 1,2-dimethoxyethane (100 mL) was slowly added to a stirred and cooled (0°C) suspension of NaH (4.0 g; 0.1 mol; 55% dispersion) in 1,2-dimethoxyethane (250 mL).
15 The reaction mixture was refluxed for 1 hour and then allowed to cool to room temperature. 3-Chloro-2-chloromethyl-propene (20 g; 0.16 mol) was added in one portion and the reaction mixture was stirred at 45°C for 40 hours. The reaction mixture was partitioned between DCM and NaHCO₃ (satd.) and the organic layer collected, dried, concentrated and purified
20 using column chromatography (DCM:MeOH; 50:1) to give the sub-title compound in a 66% yield.

(b) 4-(3-Chloro-2-hydroxy-2-hydroxymethylpropoxy)benzonitrile

N-Methyl morpholine N-oxide (490 mg; 3.64 mmol) and osmium tetroxide (80 µL; 4 wt. % solution in water) were added to a stirred solution of 4-(2-chloromethylallyloxy)benzonitrile (630 mg; 3.0 mmol; from step (a) above) in 10 mL wet acetone (12% H₂O). The reaction mixture was stirred at room temperature for 36 hours. Na₂SO₃ (1.0 g) was added and after 1 hour the solids were filtered off. The filtrate was

109
concentrated and the residue subjected to column chromatography (DCM:MeOH; 50:1) to give the sub-title compound in a 50% yield.

(c) 7-[3-(4-Cyanophenoxy)-2-hydroxy-2-hydroxymethylpropyl]-3,7-diazabicyclo[3.3.1]nonane-3-carboxylic acid *tert*-butyl ester

A mixture of 4-(3-chloro-2-hydroxy-2-hydroxymethylpropoxy)benzonitrile (180 mg; 0.74 mmol; from step (b) above), *tert*-butyl 3,7-diazabicyclo[3.3.1]nonane-3-carboxylate (230 mg; 1.0 mmol; see Example F above) and K₂CO₃ (140 mg; 1.0 mmol) in MeCN (5 mL) was refluxed for 48 hours. The reaction mixture was filtered and the filtrate concentrated. The residue was dissolved in diethyl ether and the solution was acidified with KHSO₄ (aq.). The aqueous layer was collected and NaHCO₃ (satd.) was added followed by ether extraction. The organic layer was collected, dried, concentrated and subjected to column chromatography (DCM:MeOH; 20:1) to give the title compound in a 31% yield.

¹³C NMR in D₂O (MeOH as internal standard): δ 28.49, 29.05, 30.46, 47.81, 48.55, 60.25, 60.94, 61.19, 65.15, 69.41, 70.08, 72.93, 79.78, 104.13, 115.31, 119.03, 133.91, 154.98, 161.72

FAB-MS (M + I)⁺ 431.7 (m/z)

Example 75

The title compounds of the above Examples 1 to 74 were tested in Test A above and were all found to exhibit an D₁₀ value of more than 6.0.

Abbreviations

	AcOH =	acetic acid
	ADDP =	1,1'-(azodicarbonyl)piperidine
5	aq. =	aqueous
	atm. =	atmospheres
	CBz =	benzyloxycarbonyl
	CDI =	carbonyl diimidazole
	Bu =	butyl
10	DCM =	dichloromethane
	DMF =	dimethylformamide
	DMSO =	dimethylsulfoxide
	Et =	ethyl
	EtOAc =	ethyl acetate
15	EtOH =	ethanol
	ESI =	electron spray interface
	eq. =	equivalents
	FAB =	fast atom bombardment
	h =	hours
20	IPA =	<i>iso</i> -propanol
	<i>i</i> -PrOH =	<i>iso</i> -propanol
	LC =	liquid chromatography
	HPLC =	high performance liquid chromatography
	<i>m</i> CPBA =	<i>meta</i> -chloroperbenzoic acid
25	Me =	methyl
	MeCN =	acetonitrile
	MeOH =	methanol
	mesyl =	methanesulfonate
	min. =	minutes

111


	Ms =	mesylate
	MS =	mass spectroscopy
	NADPH =	nicotinamide adenine dinucleotide phosphate, reduced form
5	NMR =	nuclear magnetic resonance
	OSu =	O-succinyl
	Pd/C =	palladium on carbon
	<i>p</i> TSA =	<i>para</i> -toluenesulfonic acid
	rt. =	room temperature
10	satd. =	saturated
	TEA =	triethylamine
	THF =	tetrahydrofuran
	tlc =	thin layer chromatography
	TMS =	tetramethylsilane

15

Prefixes *n*, *s*, *i* and *t* have their usual meanings: normal, iso, secondary and tertiary.

Claims

1. A compound of formula I,



5

wherein

- R¹ and R² independently represent H, C₁₋₄ alkyl or together form -O-(CH₂)₂-O-, -(CH₂)₄- or -(CH₂)₅-;
- 10 R⁹ represents C₁₋₁₂ alkyl, phenyl, naphthyl, C₁₋₃ alkylphenyl (which four groups are all optionally substituted or terminated by one or more substituents selected from -OH, halo, cyano, nitro, C₁₋₄ alkyl or C₁₋₄ alkoxy) or -(CH₂)_qCy¹;
- R¹⁰ represents H or -OH;
- 15 R¹¹ represents H or C₁₋₄ alkyl;
- R¹² represents one or more optional substituents selected from OH, cyano, halo, amino, nitro, C₁₋₆ alkyl, C₁₋₆ alkoxy, -N(H)S(O)₂R¹⁶, -OS(O)₂R^{16a}, -N(H)C(O)N(H)R¹⁷ or -C(O)N(H)R¹⁸;
- A represents a single bond, C₁₋₄ alkylene, -(CH₂)_nN(R²⁰)-, -(CH₂)_nS(O)_p-,
- 20 -(CH₂)_nO- (in which three latter groups, the -(CH₂)_n- group is attached to the carbon atom bearing R¹⁰ and R¹¹), -C(O)N(R²⁰)- (in which latter group, the -C(O)- group is attached to the carbon atom bearing R¹⁰ and R¹¹),

113

- N(R²⁰)C(O)O(CH₂)_n- , -N(R²⁰)(CH₂)_n- (in which two latter groups, the N(R²⁰) group is attached to the carbon atom bearing R¹⁰ and R¹¹) or -(CH₂)_mC(H)(OH)(CH₂)_n- (in which latter group, the -(CH₂)_m- group is attached to the carbon atom bearing R¹⁰ and R¹¹);
- 5 B represents a single bond, C₁₋₆ alkylene, -N(R²³)(CH₂)_r- or -O(CH₂)_r- (in which two latter groups, the -(CH₂)_r- group is attached to the bispidine nitrogen atom);
- m represents 1, 2 or 3;
- n and r independently represent 0, 1, 2, 3 or 4;
- 10 p represents 0, 1 or 2;
- q represents 0; 1, 2 or 3;
- X represents O or S;
- Cy¹ represents a five to seven-membered heterocyclic ring containing one or more heteroatom selected from O, N or S, which ring is optionally substituted by one or more substituent selected from C(O)R²¹ or C(O)OR²²;
- 15 R¹⁶, R^{16a}, R²⁰ and R²³ independently represent H or C₁₋₄ alkyl; and R¹⁷, R¹⁸, R²¹ and R²² independently represent H or C₁₋₆ alkyl; or a pharmaceutically acceptable derivative thereof.
- 20
2. A compound as claimed in Claim 1, wherein R¹ represents H, C₁₋₄ alkyl or, together with R², represents -O(CH₂)₂O- or -(CH₂)₄-.
- 25
3. A compound as claimed in Claim 1 or Claim 2, wherein R² represents H or, together with R¹, represents -O(CH₂)₂O- or -(CH₂)₄-.
4. A compound as claimed in any one of the preceding claims, wherein R⁹ represents optionally substituted phenyl, optionally substituted C₁₋₃ alkylphenyl, optionally substituted, optionally unsaturated, linear, branched

114

or cyclic, C₁₋₁₂ alkyl (which latter group may also be interrupted by an O atom), or -(CH₂)_qCy¹.

5. A compound as claimed in Claim 4, wherein R⁹ represents linear or
5 branched C₂₋₇ alkyl.

6. A compound as claimed in any one of the preceding claims, wherein R¹⁰ represents -OH.

10 7. A compound as claimed in any one of the preceding claims, wherein R¹¹ represents H, CH₃ or CH₂OH.

15 8. A compound as claimed in any one of the preceding claims, wherein R¹² is absent or represents one or more substituents selected from cyano, OH, nitro, N(H)SO₂R¹⁶, N(H)C(O)N(H)R¹⁷, C(O)N(H)R¹⁸, OS(O)₂R^{16a}, amino and C₁₋₆ alkyl.

20 9. A compound as claimed in Claim 8, wherein, when R¹² is in the *para*-position, it represents cyano, nitro or N(H)S(O)₂R¹⁶ (in which R¹⁶ represents C₁₋₃ alkyl).


10. A compound as claimed in any one of the preceding claims, wherein X represents O.

25 11. A compound as claimed in any one of the preceding claims, wherein A represents a single bond, O, -CH₂-, -(CH₂)₂-, -CH₂O-, -(CH₂)₂O-, -CH₂S-, -CH₂N(R²⁰)-, -C(O)N(R²⁰)-, -N(R²⁰)C(O)O(CH₂)_n-, -CH₂CH(OH)- or N(R²⁰)(CH₂)_n-.

115

12. A compound as claimed in any one of the preceding claims, wherein B represents optionally unsaturated, linear or branched, C₁₋₄ alkylene (which group is also optionally interrupted by O).
- 5 13. A compound as claimed in any one of the preceding claims, wherein, when the bispidine nitrogen bearing B also bears a C₁₋₄ alkyl group, thus forming a quaternary ammonium salt, the alkyl group is methyl.
- 10 14. A compound as claimed in any one of the preceding claims, wherein, when R⁹ represents -(CH₂)_qCy¹, q is 0, 1 or 2 and Cy¹ contains at least one nitrogen atom.
- 15 15. A pharmaceutical formulation including a compound as defined in any one of Claims 1 to 14 in admixture with a pharmaceutically-acceptable adjuvant, diluent or carrier.
- 20 16. A pharmaceutical formulation for use in the prophylaxis or the treatment of an arrhythmia, comprising a compound as defined in any one of Claims 1 to 14.
17. A compound as defined in any one of Claims 1 to 14 for use as a pharmaceutical.
- 25 18. A compound as defined in any one of Claims 1 to 14 for use in the prophylaxis or the treatment of an arrhythmia.
19. The use of a compound as defined in any one of Claims 1 to 14 as active ingredient in the manufacture of a medicament for use in the prophylaxis or the treatment of an arrhythmia.

20. The use as claimed in Claim 19, wherein the arrhythmia is an atrial or a ventricular arrhythmia.
- 5 21. A method of prophylaxis or treatment of an arrhythmia which method comprises administration of a therapeutically effective amount of a compound as defined in any one of Claims 1 to 14 to a person suffering from, or susceptible to, such a condition.
- 10 22. A process for the preparation of a compound of formula I as defined in Claim 1 which comprises:
- (a) reaction of a compound of formula II,




15

wherein R¹, R², R¹⁰, R¹¹, R¹², A and B are as defined in Claim 1 with a compound of formula III,




wherein L¹ represents a leaving group and R⁹ and X are as defined in Claim 20 1;


(b) for compounds of formula I in which B represents CH₂ and R¹⁰ represents OH, reaction of a compound of formula IV,



wherein R¹, R², R⁹ and X are as defined in Claim 1, with a compound of
5 formula V,




wherein R¹¹, R¹² and A are as defined in Claim 1;
10 (c) reaction of a compound of formula IV, as defined above, with a
compound of formula VI,



15 wherein L² represents a leaving group and R¹⁰, R¹¹, R¹², A and B are as
defined in Claim 1;

118


(d) for compounds of formula I in which R¹¹ represents H, reduction of a compound of formula VIII,



5

wherein R¹, R², R⁹, R¹², A, B and X are as defined in Claim 1;

(e) for compounds of formula I in which R¹ and R² both represent H, reduction of a corresponding compound of formula IX,



10

wherein R⁹, R¹⁰, R¹¹, R¹², X, A and B are as defined in Claim 1, and in which the C=O group may be activated;

(f) for compounds of formula I in which R¹ and R² together represent

119

-O(CH₂)₂O-, reaction of a corresponding compound of formula IX, as defined above, with ethane-1,2-diol;

5 (g) for compounds of formula I which are bispidine-nitrogen N-oxide derivatives, oxidation of the corresponding bispidine nitrogen of a corresponding compound of formula I;

(h) for compounds of formula I which are C₁₋₄ alkyl quaternary ammonium salt derivatives, in which the alkyl group is attached to a bispidine nitrogen, reaction, at the bispidine nitrogen, of a corresponding compound of formula I with a compound of formula XI,

10




XI

wherein R^b represents C₁₋₄ alkyl and Hal represent Cl, Br or I;


(i) for compounds of formula I in which R¹⁰ and R¹¹ represent H, B represents C₁₋₆ alkylene and A represents -N(R²⁰)(CH₂)_n-, reaction of a compound of formula XII,

15



wherein B^a represents C₁₋₆ alkylene and R¹, R², R⁹, R²⁰ and X are as defined in Claim 1, with a compound of formula XIII,

20



120

wherein R¹² and n are as defined in Claim 1 and Hal is as defined above;

(j) reaction of a compound of formula II, as defined above, with a compound of formula XIV,




5 wherein R⁹ and X are as defined in Claim 1, in the presence of 1,1'-carbonyldiimidazole; or

(k) conversion of one R¹² substituent to another.

10 23. A compound of formula IV, as defined in Claim 22, or a protected derivative thereof.

24. A compound of formula IX, as defined in Claim 22, or a protected derivative thereof.


15 25. A compound of formula XVI,



20 wherein R¹⁰, R¹¹, R¹², A and B are as defined in Claim 1, or a protected derivative thereof.

121


26. A compound of formula XVIII,



5 wherein R⁹ and X are as defined in Claim 1, or a protected derivative thereof.

27. A process for the preparation of a compound of formula IX, XVI or XVIII, which comprises reaction of (as appropriate) either:

10 (i) a compound of formula XXIX,




wherein R⁹ and X are as defined in Claim 1; or

(ii) 4-piperidone,

with (as appropriate) either

15 (1) a compound of formula XXXI,

122



xxxI

wherein R¹⁰, R¹¹, R¹², A and B are as defined in Claim 1; or

(2) NH₃,

5 in all cases in the presence of a formaldehyde.

28. A process as claimed in Claim 27, in which the reaction is carried out in the presence of an organic acid

10 29. A process as claimed in Claim 28, in which the organic acid is acetic acid.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE 98/02276

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: C07D 471/08, C07D 471/20, A61K 31/435
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0308843 A2 (BASF AKTIENGESELLSCHAFT), 29 March 1989 (29.03.89), see especially reaction schemes A, B and C concerning intermediate compound XVI	1-20,22-23
X	--	25
A	WO 9107405 A1 (THE BOARD OF REGENTS OF OKLAHOMA STATE UNIVERSITY), 30 May 1991 (30.05.91)	1-20,22-23
A	EP 0306871 A2 (KALL-CHEMIE PHARMA GMBH), 15 March 1989 (15.03.89)	1-20,22-23
	--	

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:	
"A"	document defining the general state of the art which is not considered to be of particular relevance
"E"	earlier document but published on or after the international filing date
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O"	document referring to an oral disclosure, use, exhibition or other means
"P"	document published prior to the international filing date but later than the priority date claimed
"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X"	document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y"	document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&"	document member of the same patent family

Date of the actual completion of the international search
29 April 1999

Date of mailing of the international search report
05-05-1999

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. + 46 8 666 02 86

Authorized officer
Göran Karlsson
Telephone No. + 46 8 782 25 00

INTERNATIONAL SEARCH REPORT

Int'l. application No.

SE 98/02276

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: 21
because they relate to subject matter not required to be searched by this Authority, namely:
A method for treatment of the human or animal body by therapy, see rule 39.1

2. Claims Nos.: 27-29
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
See extra sheet

3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

See extra sheet

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest



The additional search fees were accompanied by the applicant's protest.



No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 98/02276

The subjects, defined by the problems and their means of solution, as listed below are so different from each other that no technical relationship or interaction can be appreciated to be present so as to form a single general inventive concept. The acceptance of a single general inventive concept covering the end products as well as products used to prepare these and products (intermediates) implies that when several claimed intermediates are implied in different reactions, these intermediates are technically closely inter-connected with the end products as well as with themselves by their use for incorporation of the same essential structural part into the end products.

This is not the case for the intermediates stipulated in claims 24, 25 and 26.

Therefore, a single general inventive concept based on the relationship intermediates/end products is lacking and this leads to subjects as listed below, each falling under its own restricted inventive concept, defined by the nature of the essential structural part present in each intermediate and incorporated into the end product(s).

Invention 1. Claims 1-20, 22 and 23 compound IV

Invention 2. Claim 24 compound IX

Invention 3. Claim 25 compound XVI

Invention 4. Claim 26 compound XVIII

Claims 27-29 are obscure and do not clearly define the matter for which protection is sought, see Article 6.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 98/02276

Claims 27-29 are obscure, and do not clearly define the matter for which protection is sought, see e.g. "which comprises reaction of (as appropriate) either". Further, they have not been shown to be characterised by the same technical feature as the invention in claim 1. A common special technical feature is not considered to exist between formula IX, XVI and XVIII in claim 27. A meaningful search has therefore not been performed, cf. Article 6.

INTERNATIONAL SEARCH REPORT

Information on patent family members

07/04/99

International application No.
PCT/SE 98/02276

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0308843 A2	29/03/89	SE 0308843 T3 DE 3732094 A DE 3886327 D JP 1102078 A US 4959373 A	06/04/89 00/00/00 19/04/89 25/09/90
WO 9107405 A1	30/05/91	US 5084572 A US 5110933 A	28/01/92 05/05/92
EP 0306871 A2	15/03/89	AU 2200588 A DE 3730222 A DE 3886145 D DK 498988 A ES 2061580 T FI 884138 A JP 1068372 A PT 88381 A,B US 4912113 A DD 282228 A DE 3730224 A	23/03/89 30/03/89 00/00/00 10/03/89 16/12/94 10/03/89 14/03/89 30/06/89 27/03/90 05/09/90 23/03/89

THIS PAGE BLANK (USPTO)